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Abstract
BAD is a Central Player in Cell Death and Cell Cycle Regulation in Breast Cancer
Cells
The estrogen, 17-β estradiol (E2) can stimulate proliferation or induce differentiation or
death depending on the cell context. In MCF 7 cells, an estrogen receptor (ER) positive
human breast cancer cell line, E2 has been shown to stimulate cell proliferation and may
have an anti-apoptotic effect. E2 rapidly activates mitogen activated protein kinases
(MAPKs) in mammalian cells in an ER dependent fashion. The mechanisms underlying
and the physiological significance of the signaling through MAPK remain to be
determined. This signal pathway may represent a potential mechanism by which E2
regulates cell proliferation, growth as well as apoptosis. Recent observation of Raf-1
kinase (which relays signals from cell surface receptor tyrosine kinase to MAPKs)
activation by E2 in MCF 7 cells explained a possible link between cell surface and
intracellular components of the signaling pathway. PI-3 kinase and its down stream
member protein kinase B (PKB/Akt) have been shown to be strongly involved in
mitogenic and anti-apoptotic signaling in MCF 7 cells.
Chemical and biological inhibition of PI-3 kinase diminished E2 supported cell
survival and concomitant Akt, MAPK (ERK) and its down stream target p90RSK
activities. On the other hand, interference of endogenous Ras with a dominant negative
construct abolished signal mechanisms involving ERK as well as Akt. These
observations suggested that Ras/ERK and PI-3 Kinase pathways could operate as
separate entities or cross talk and cooperate to enhance survival or impede apoptosis in
MCF 7 cells in the presence of E2.
BCL2 family proteins play critical decision-making roles during apoptosis. BH3
domain only, pro-apoptotic member, BAD has been intensively investigated for its
contribution in regulation of apoptosis at the mitochondrial level. Post-translational
phosphorylation modulates BAD’s function and, most survival factors impose inhibitory
phosphorylations on BAD via active Akt and MAPK pathways.
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E2 rapidly induces Akt and ERK signaling pathways resulting in phosphorylation
of BAD on two serine residues, and abolishes apoptosis in response to a variety of stimuli
in MCF-7 cells. Therefore, we hypothesized that E2 targets BAD for its anti-apoptotic
effect. Data presented clearly show that E2 effects are at least partly mediated via Ras
originated ERK/p90RSK and PI-3 kinase/Akt pathways that add inhibitory phosphate
groups onto corresponding serine 75 and 99 residues of BAD there by inactivating its
pro-apoptotic tendencies. We demonstrate the significance of BAD and its functional
serine residues in E2 mediated anti-apoptosis with studies conducted with anti-sense
mRNA and phosphorylation site mutants of BAD. Over-expression of wild type or
phosphorylation site mutant of BAD did not enhance the basal cell death, which was
remarkably lessened by the inhibition of endogenous BAD. E2 could rescue cells from
TNFα induced death in control cultures and in wild type BAD transfected cells but not in
phosphorylation site mutant BAD expressing cells. This observation agrees with
previous studies that demonstrate the importance of BAD’s phosphorylation sites in
growth factor mediated cell protection. This study shows for the first time that E2 is an
anti-apoptotic agent in breast cancer cells whose response is mediated by non-genomic
cytoplasmic signal networks that converge on BAD in turn regulating the mitochondrial
membrane potential change.
When transiently over-expressed, wild type or dual phosphorylation site mutant of
BAD did not induce apoptosis, as observed in the first part of this study, but the rate of
growth of these cells was remarkably low compared to the untransfected or control vector
transfected cells. This suggested that the presence of extra amount of BAD could reduce
the growth of MCF-7 cells. Similar phenomenon have been reported with the
overexpression of BCL2 in malignant as well as normal epithelial cells. When over
expressed, BCL2 arrests cell cycle in G0/G1 phase and this effect appears to depend on
the amino terminal BH4 domain. Interestingly in a variety of epithelial cell types,
endogenous BCL2 was shown to localize to the chromosomes of mitotic nuclei. This
pattern of BCL2 expression is considered to be indicative of its special role in cell
proliferation.
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We hypothesized that BAD also exhibits a cell cycle related function in breast
cancer epithelial cells, which was tested in the second part of this study. We evaluated
the distribution pattern of nuclear BAD in several breast cancer cell lines. BAD
overexpression lessened cyclin D1protein levels that agreeably correlate with the G1-S
transition block observed. Cyclin D1 regulation by BAD was assayed at the
transcriptional level using a luciferase reporter under the control of the cyclin D1
promoter. In asynchronous cells and in synchronous and E2 treated cells, BAD overexpression significantly reduced the cyclin D1 reporter activity. Overexpression of a
dual phosphorylation site mutant of BAD did not alter the cyclin D1 expression pattern or
the cell cycle progression suggesting an involvement of these serine residues in BAD’s
nuclear functions. Furthermore, the BH3 domain deletion mutant and the S91A mutant,
both of which carry intact S75 and S99 residues, exerted inhibitory effects similar to that
of wild type BAD.
Wild type BAD overexpression as well as BAD depletion from nuclear extracts
diminished the labeled AP-1/TRE DNA binding with the nuclear factors. This
demonstrates that BAD is capable of binding and sequestering some components from
the nuclear extracts which bind with AP-1/TRE element. Collectively our data suggest
that in addition to pro-apoptotic functions, BAD regulates the cell cycle at least partly via
AP-1/TRE element. These functions appear to depend on its S75 and S99
phosphorylation status that are also the targets of pro-survival mechanisms. Further,
these results also suggest that the AP-1 transcription regulation by BAD is kept at its
minimal level in normal cells as a result of the fine balance of its phosphorylation state.
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Chapter 1
Signal Pathways that Mediate 17-β Estradiol Induced Anti-apoptosis in
Breast Cancer Cells
1.1 Introduction
1.1.1 Cancer
Cancer cells are characterized by two heritable properties; they (i) reproduce in defiance
of normal restraints, and (ii) invade and colonize surrounding tissue and distant sites
constituting the phenomenon, metastasis. Fundamental properties of malignancy are
encoded in genes of the cancer cell, as evident by the inheritance of malignant traits by its
progeny. Studies of genetic markers in cancers indicate a given human tumor is derived
from a single cell (e.g. expression of unique immunoglobulin molecules in lymphomas
and myelomas, translocation of chromosomes 9 and 22 (Philadelphia chromosome) in
chronic myelogenous leukemia). However, further genetic changes as well as other
environmental factors could result in a heterogeneous population of cancer cells in a
given tumor and this heterogeneity may affect many aspects of cancer development i.e.
invasiveness, resistance to tumor therapy and metastatic properties, hence the tumor
progression.
Much of current cancer research is directed to the identification and
characterization of genes whose products are involved in the transformation of a normal
to a malignant cell. These studies led to the identification of oncogenes, where a
mutation causes a change in a normal cellular protein that could lead to malignant change
in the cell. These genes are dominantly acting since only one copy of the gene has to
undergo the mutation. Many of these gene products are important in the normal
transmission of growth-promoting signals from cell surface to the nucleus (e.g. src, ras),
transcription regulation (e.g. myc, c-jun), or regulation of cell death (e.g. bcl2). The other
class of genes, tumor suppressors, acts to suppress the malignant transformation in
normal cells (e.g. Rb, p53, BRCA1 and 2). Both copies of the tumor suppressor gene
must be lost, mutated or inactivated for malignant transformation. In normal tissue, there
is a balance between cell proliferation and cell death. In tumors, this balance is disturbed
1

perhaps because of genetic defects that lead to abnormal cell proliferation and death.
Aberrant cell proliferation and death rarely coincide as does the occurrence of cancer.
Increased proliferation consequently triggers cell death and the reduced cell death is not
significance in the absence of enhanced proliferation (103). This natural interdependency
of the two key mechanisms keeps the tissue balanced. Accumulation of genetic damages
in cells hinders their ability to restrain or counteract abnormal cellular processes.
Acquisition of independency from mitogenic stimuli and noncompliance to growth
inhibitory signals could be the result of such genetic mutations. Telomere erosion, which
sets control for endless cell division is the next obstacle that sustained cell proliferation
has to overcome. Telomeres are the long non-transcribed regions at the ends of
chromosomes. As a result of repeated DNA replication these structures shortens and this
phenomenon is termed as telomere erosion. The enzyme that repairs the eroded
telomeres, telomerase is expressed in limited fashion in somatic cells; therefore the
somatic cells are allowed only a limited number of cell divisions (105). Telomerase upregulation has been observed in cancer (18).
Characterization of cell proliferation and death in cancer has provided the
information that contrary to general belief, tumor cells usually proliferate more slowly
than cells in normal tissues, such as the intestinal epithelium and bone matrix. A
relatively small proportion of tumor cells may retain the capacity for unlimited
proliferation and these stem cells are the important targets of cancer therapy.
Furthermore, tumors have a high rate of cell death perhaps as a result of limited supply of
nutrients, through the process of programmed cell death and /or necrosis (72). Also, the
over-expression of oncogenes has been shown to induce apoptosis in tumors
(75,122,151).
It has been suggested that immune surveillance may eradicate some tumors before
their clinical detection. Expression of ‘non-self’ molecules such as the products of
mutated oncogenes, which differ from those in normal cells, could promote an immune
rejection response. Therefore, the tumors that either do not express these ‘non-self’
molecules or have mechanisms allowing them to evade the immune rejection response
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may continue to grow (1). This type of information has led to the efforts to devise
therapies that might induce tumor rejection by the host.
In solid tumors there are interactions between the constituent cells and the extra
cellular matrix (ECM). These interactions may be modulated by growth factors and
hormones that interact with specific receptors and propagate signal and gene expression,
and adhesion molecules that interact with ECM components and initiate intracellular
signaling (46,181,215). The ECM provides the surface for the cell attachment and a
barrier for cell movement. Therefore, breakdown of extra cellular components through
secretion of proteolytic enzymes (e.g. metalloproteinases, Cathepsins), which is thought
to be an important mechanism in metastasis (229), may also assist in invasion, growth
and the angiogenesis of a tumor. The inhibition of these proteases has been recognized as
potential strategy to suppress tumor growth (88). Further, proper attachment of
transformed as well as untransformed mammary epithelial cells to the ECM was shown
to enhance their anti-apoptotic capacity. This acquired resistance to apoptosis depends, at
least in part on NFκB mediated signaling, which was activated in this system by the
interaction of epithelial integrin and the ECM (283).
In order to sustain the growth, a solid tumor has to elicit the proliferation of blood
vessels that provide nutrition to the cancer cells and remove catabolic products. This
process of angiogenesis is stimulated by the release of several growth factors from tumor
cells as well as the surrounding normal cells. Vascular endothelial growth factor (VEGF)
has been shown to vastly contribute to this process. The synthesis and release of VEGF
is stimulated by the hypoxic environment (223). Upregulation of VEGF and
angiogenesis has also been observed in response to constitutive activation of other
oncogenic proteins (e.g. EGFR, Raf, MEK, PI3K) acting at various levels on the Ras
signaling pathway (219). Interestingly, a stronger expression of VEGF was observed in
the surrounding stroma but not in the tumor in an animal model (97). This finding that
the VEGF promoter of non-transformed cells is strongly activated by the tumor
microenvironment may point to a need to analyze and understand the stromal cell
collaboration in tumor angiogenesis.
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While clinical observation has divided tumor development into a number of discrete
categories of severity (benign, malignant, metastatic), the underlying biology can be
described as a process of many changes. The genetic changes can affect the cell’s growth
potential, and the cells with such changes are selected for (or against) by the conditions
they are exposed to. Increasing knowledge of signal transduction pathways in cells has
demonstrated that many aspects of cell function are controlled by a balance of positive
and negative signals received from inside and the outside of the cell. Thus the lack of
ability or increased ability to respond to a specific signal may allow the cell to proliferate
in the face of other signals that would normally prevent such proliferation. Cancer
treatment can be considered as adding negative signals to the cellular environment. The
process of genetic change may give rise to a subpopulation of cells that have evolved
varied mechanisms of drug resistance, and these cells could survive and re-grow the
tumor following chemotherapy. The genetic evolution of cancer cells and the signal that
the cells receive from their extra cellular environment therefore could play critical roles
in the growth and treatment of cancers (1).

1.1.2 Estrogen
Synthesis, Metabolism and Physiological Importance
Estrogens, an important class of steroid hormones, influence growth, differentiation and
functions of many target tissues. All naturally occurring estrogens (estrone, estradiol and
estriol) are C18 steroids secreted by the theca interna and granulosa cells of the
developing ovarian follicle, corpus luteum as well as the placenta. Estrogens are also
produced by aromatization of androgens in adipose tissue, liver, skin and in breast
epithelial cells. Both estrogens and precursor androgens are derived from cholesterol.
The most potent naturally occurring estrogen, 17-β estradiol (E2) is found in both free
and protein bound forms in the circulation (Figure 1.1.2.1). After synthesis, E2 is
secreted into the blood stream where it binds with sex-hormone-binding globulin and
albumin. Free estrogens diffuse into target tissues to exert their specific genomic or nongenomic effects. Enzymatic catabolism of estrogens yields the hydroxyl-estrogens and
methoxy-estrogens (107). In the liver, estrogens are conjugated to sulfate or gluconate
4

Promotes
breast cancer

Modified from NEJM 346: 340-352

Figure 1.1.2.1
Synthesis, metabolism and physiological importance of estrogen
See text for details

5

and made water-soluble. Then they are excreted by billiary secretion and a major part of
it is reabsorbed prior to urinary passage (2).
Besides stimulating development and maturation of the female reproductive
structures and secondary sexual characteristics, estrogens are necessary for cyclic
endometrial changes that are important for reproduction, development of breast tissue,
health of the skin and bone homeostasis. Estrogenic effects on blood coagulation,
endothelial cells, intestinal motility, cholesterol metabolism and sodium and water
conservation by renal tissue have also been appreciated giving estrogen a remarkable
importance in the normal physiology (123,228). Importance of estrogen in male fertility,
specifically to sperm count was reported recently. This study focused on the regulatory
role of estrogen - induced fluid absorption during the transfer of sperm in fluid from the
testis through the efferent ductules to the epididymis (116). Some pesticides such as
DDT and many industrial chemicals have estrogenic or anti-estrogenic properties and
may have deleterious effects on male and female health. Declining sperm counts all
around the world is regarded as a reflection of the adverse effects of estrogenic
compounds on male fertility (236).

Estrogen Receptors, Classical vs. Non-Classical Functions of Estrogen
Many of the diverse biological effects of sex steroids are hypothesized to occur as
follows: the hormone enters the cytoplasm by diffusion, translocates to the nucleus,
interacts with nuclear receptor, and binds DNA resulting in transcriptional activation of
steroid responsive genes. The estrogen receptor (ER) when unattached to the ligand is
loosely bound in the cytoplasm by a host of chaperone proteins. These molecules
function to stabilize the receptor in the inactivated state, prevent the receptor from
binding to the DNA elements, and contribute to cross-talk among different signal
pathways (249,260,270). The exact location of the ER-chaperone complex is still
uncertain. The possibility is that there is an equilibrium distribution between the
cytoplasm and the nucleus that could be shifted upon the stimulation with the estrogenic
ligand. When free estrogen diffuses into the cell, it binds with the ligand-binding domain
of the ER. The chaperones dissociate and estrogen-ER complex then migrates to the
6

nucleus and bind to specific sequences of DNA called estrogen response elements (ERE,
5’GGTCAnnTGACC3’ where n=any nucleotide). This DNA binding requires ER to be
dimerized (287). A host of ERE carrying genes has been defined (Table 1.1.2.1). The
estrogen-receptor complex not only binds to the EREs, but to co-activators or repressors
thereby adding levels of regulation to the transcriptional activities of estrogen. Estrogens
also regulate the transcription of genes that lack functional EREs by interacting with
other nuclear factors. As an example, ER interacts with activating protein-1 (AP-1)
subunits and modulates AP-1 dependent gene transcription (274).
Two types of nuclear ER, α and β which carry out estrogen-induced gene
activation upon ligand binding have been demonstrated, depicting the classical steroidal
hormone-receptor function. However the effects of nuclear cofactors on ERα and β
ligand binding and the correlation of ligand binding and gene transactivation have not
been completely resolved yet. Both isoforms are reported to originate from a single
transcript and have near-identical affinities for E2 (225) though their tissue distribution
and functional mechanisms seems to differ considerably. ERα predominates in breast
and uterine tissues (154) whereas ERβ is expressed in the central nervous system,
endothelial cells and urogenital systems (Figure 1.1.2.2 (B)) (287). Though both
receptors share many structural similarities (Figure 1.1.2.2 (A)) their functional
differences may add to the existing complexity of estrogenic effects. The main difference
between them lies within the AF-1 transactivation domain, which is inactive or even
repressive in ERβ (109,154,296) in contrast to ERα whose AF-1 is active by itself.
Interestingly both isoforms have virtually identical DNA binding domains suggesting that
ERα and β interact with similar response elements. Outcome and level of maintenance
of activated signal cascades by both receptors differ in the presence of estrogen agonists
and antagonists. Several lines of human breast cancer cells and about 70% of breast
cancers at initial diagnosis express estrogen receptors. About 50% of these tumors are
dependent on E2 for growth as evidenced by studies with anti estrogens (32,254).
Estrogen and ER duet could yield to a magnitude of alternative pathways that may
contribute to non-classical, non-genomic functions, some of which have been already
described. As for many other nuclear receptors, ligand independent activation of ER
7

Table 1.1.2.1
List of Putative Estrogen /ER Target Genes
Modified from Genome Biology 5:R66
Gene name

Function

8

Ligand binding,
NLS,
dimerization

(A)
hinge

A/B

302

263

180
C

D

595

553
F

E

Human ERα

AF-2

AF-1
Ligand independent
transactivation
function

Dimerization,
DNA binding

15%

97%
148

Ligand dependent
transactivation
function

60%

30%
214

304

Proteolysis of the
receptor

17%
500

Human ERβ

530

(B)

Figure 1.1.2.2
Structure and tissue distribution of estrogen receptors (α and β)
(A) Structure of human estrogen receptors. Function of various regions of the receptor
are indicated in boxes. Numbers in red indicate position of amino acid residues.
% indicates the percent homology between ERβ to ERα
(B) General distribution of both receptors in human
9

(mostly ERα) has been reported. ERs are members of the steroid hormone receptor
family that are regulated by phosphorylation of tyrosine and serine residues. Changes in
the phosphorylation could invariably modulate their function. Growth factors and other
agents may possibly activate/inactivate these receptors through the activity of their
downstream protein kinases. Phosphorylated sites vary depending on the identity of the
activated kinase/s, thereby adding more intricacies to the receptor function. For an
instance, PI-3 Kinase/Akt pathway phosphorylates ERα at consensus serine 167
activating the receptor. This activity confers protection against anti-estrogen therapy in
breast cancer cells (43) possibly through blocking ER and anti-estrogen interaction.
Similarly, resistance to tamoxifen was shown to be mediated by PKA through its target
serine 305. Upon phosphorylation of this site, ERα was unable to acquire the inhibitory
conformation when bound to tamoxifen, and this led to growth stimulation in the
presence of this anti-estrogen (191). Additionally, serine 104, 106, 118 and 126 as well
as tyrosine 357 have been identified as potential targets of various kinases and their
phosphorylations appear to activate the receptor function.
Although in vitro studies suggest the two species of ER may play redundant roles,
a dissimilar tissue distribution indicates otherwise. Therefore the generation of mice
lacking individual or both ER forms was a very effective tool. Summary of reported
phenotypes of ER null mice are shown in Table 1.1.2.2 (62). ERα appears to be critical
for the reproductive function in both male and female mice, where as ERβ holds an
intermediary effect. It is logical to argue that known genomic effects of estrogen are
mostly mediated by the major isoform, ERα. ERβ appears to show some redundancy in
its function in certain tissues. ERβ has been shown to posses opposing effects in
response to estrogenic ligands (162), and may play a crucial role in maintaining a
balanced state of estrogen effect on a particular tissue. This information should be born
in mind when interpreting data of knock out studies. A single knock out may not
necessarily provide the critical information regarding the particular ER; rather the effect
may be the combination of that as well as the unchecked action of the other ER.
The genomic mechanism of estrogen described above is unlikely to explain the
rapid effects observed in target tissues such as bone, vasculature, neural, uterus and breast
10

Table 1.1.2.2
Phenotypes of ER Deficient Mice (modified from Endocrine Reviews 20: 358-417)
ER knock out model
Lethality of mutation
ERα KO
ERβ KO
Fertility
ERα KO
ERβ KO
General
ERα KO
ERβ KO

Female reproductive tract
ERα KO

ERβ KO

Mammary gland
ERα KO

ERβ KO

Phenotype

No
No
Both sexes are infertile
Female is subfertile (reduced litter size); males
fertile
Exhibit normal expression of the ERb gene
Exhibit normal expression of the ERa gene
Tract undergoes normal pre- and neonatal
development but is insensitive to E2
Responsive to mitogenic actions of androgens
Ovaries undergo normal pre- and neonatal
development, but are anovulatory during adulthood,
exhibit multiple hemorrhagic cysts, and no corpora
lutea
30–40% incidence of ovarian tumors by 18 months
of age
Tract undergoes normal pre- and neonatal
development and appears sensitive to ovarian
estrogen cycling during adulthood

Undergoes normal prenatal development but is
insensitive to estrogen-induced development during
puberty and adulthood
Responsive to exogenous progesterone and
prolactin
Undergoes normal prenatal and pubertal
development, virgin gland is grossly
indistinguishable from that of age-matched wildtype
Undergoes normal differentiation and lactation
during pregnancy and motherhood

11

Table 1.1.2.2 continued
ER knock out model
Male reproductive tract
ERα KO

ERβ KO

Phenotype
Tract undergoes normal pre- and neonatal
development
Age-related phenotype of attenuated fluid
resorption in efferent ducts leads to dilation of
Rete testis, atrophy of the seminiferous
epithelium, and decreasing sperm counts
Disrupted sperm function -inability to fertilize
Age-related decreases in testis weight
Age-related increases in seminal vesicle weight
Undergoes normal pre- and neonatal
development with no apparent defects in
spermatogenesis that impede fertility

Cardiovascular system
ERα KO

reduced estradiol-induced angiogenesis
and reduced basal levels of vascular nitric
Oxide

Behavior – Females
ERα KO

Exhibit a lack of estradiol and progesterone-induced
sexual behavior, increased aggression,

ERβ KO

Exhibit no defects in sexual behavior that impede
fertility

Behavior – Males
ERα KO

Exhibit normal mounting and attraction toward
wild-type females but a complete lack of
intromission and ejaculation; display reduced
aggression
Exhibit no defects in sexual behavior that impede
fertility

ERβ KO
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tissue (214). These effects do not fit into the time frame of classical genomic activity and
suggest the existence of rapid, non-genomic activity. Recent reports clearly show that E2
is capable of activating kinase-regulated signal transduction pathways in MCF-7 and
other cell lines (7,117,192,245). Most of these studies further elaborate cell/tissue
context specific estrogenic activities. Further investigation into the estrogen signaling
mechanisms has led to the hypothesis of cell surface estrogen receptors that could be
coupled to cytosolic signal transduction pathways. Membrane impermeable estrogens
(E2-BSA) have been used to demonstrate possible membrane associated functions for
decades. Even though many signal cascades have been defined as response to these
compounds, it is important to appreciate the inherent difficulties of the approach such as
leakage of minute, undetectable levels of E2 that could signal the cellular responses.
Expression of ER in cells lacking endogenous ER has been useful and it has
tremendously helped to delineate signal networks associated with ER, yet it is not without
setbacks. Artificial expression of the molecule doesn’t always guarantee its optimum
function. Lack of factors that are indispensable for ER action (and present in naturally
ER positive cells) could retard the receptor function in the new environment. On the
other hand, exogenously expressed ER may interact with host cell specific molecules
producing unrelated effects. Therefore information from this type of studies should be
interpreted with caution.
Evidence for exclusively membrane bound ER in many cell types is slowly
emerging. Studies where overexpression of membrane anchored ERα was used to
activate cytoplasmic signal transduction pathways (167) have attempted to explore the
significance of membrane bound ER. Consequently, the structural determinant that is
necessary for the localization and function of ERα at the plasma membrane was
determined (224). Mutation of a specific serine phosphorylation residue (S522) to
alanine significantly reduced the membrane localization of mouse ERα and the
expression of this mutant in ER expressing cells abolished the binding of native ERα to
the membrane. Interestingly, the nuclear function of this mutant was comparable to that
of wild type ER in response to E2. Determination of the exact amounts of exclusively
membrane bound and nuclear ER levels may pose difficulties since ER constantly shuttle
13

between the nucleus and the cytoplasm, despite its predominantly nuclear localization
(195). Based on microscopic evidence it is worth to speculate that the membrane pool of
ERα represents a small proportion of the total immunoreacting receptors (189,195,224).
Interpretation of data from ligand (estrogen) binding studies should also be done with
caution since other estrogen binding entities that are not related to ER have been reported
(275).
In physiological condition the signaling mechanisms described above may operate
as individual entities or may co-exist and interact. The latter will add up to the existing
complexity of our understanding in estrogenic effects. Genomic, non-genomic, classical
and non-classical activities of E2 and ER are demonstrated in the Figure 1.1.2.3.

Estrogen and Breast Cancer
Estrogen and the Development of Breast Tissue
The fundamental feature of breast cancer is that it occurs far more frequently in women
than in men, although men have breast tissue and sometimes get breast cancer. Genetics,
hormonal milieu and environment, all participate in the pathogenesis of breast cancer for
a greater or lesser extent. Presence of higher levels estrogen appears to act on the breast
to make it susceptible for tumor formation in females. In males, the plasma concentration
and the production rate of estrogen are significantly lower than that in females (Figure
1.1.2.4). The inverse relationship is true for the level of testosterone in males and
females. This fundamental difference of hormone levels is the key to the distinct male
and female physiologies. Such differences could also make one gender more susceptible
to specific disorders than the other.
Development of the breast tissue in female is a characteristically regulated by the
action of estrogen (Figure 1.1.2.4). Unlike the tissues that are fully formed at birth,
breast tissue in newborns consists only of a small duct, which grows rapidly at puberty
and completes full growth only after the first pregnancy (2). The internal breast
structures begin to expand rapidly under the influence of estrogen. Typically a girl's first
period will begin about a year or two after her breasts begin to grow. With every
menstrual cycle a new phase of growth occurs which includes extensive branching of the
14

Modified from NEJM 346: 340-352

Figure 1.1.2.3

Functional diversity of E2-ER
ER can be activated by 17-β-estradiol (E2) or independently of estrogen. Growth factors
indirectly activate ER by increasing the activity of protein kinases which phosphorylate
sites on ER. In the case of non-nuclear estrogen signaling pathway, cell membrane
bound ER that may be found in caveolae, link their activity to mitogen activated protein
kinase pathways. This results in rapid nonnuclear effect.
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Steroid

Male
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Estradiol

Early follicular 6
Late follicular 50
Mid follicular 20

Progesterone
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3
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FSH
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Onset of menstruation
Range
Breast development

Figure 1.1.2.4
(A) Plasma concentrations of female and male gonadal steroids
(modified from Physiology 2nd edition chap55 pgs 998, 1000)
(B) Average chronological sequence of hormonal and biological events in normal
female puberty (modified from Physiology chap 55 pg1015)
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ductal system and organization of the internal structures. The immature breast cells are
inefficient in repairing gene mutations and more likely to bind carcinogens. It is
important to reduce the exposure of young women and girls to carcinogens that might
damage DNA during the rapid phase of breast development. After first full term
pregnancy, a high proportion of breast cells are transformed to mature, differentiated cells
that are less sensitive to DNA damaging agents. Therefore susceptibility to mutations
and resulting carcinogenesis may decline in the breast cells of women who have had an
early full-term pregnancy (179). Accordingly, increased risk of breast cancer in
nulliparous women can be explained. Similar level of risk has been observed in females
who did not complete a full term pregnancy before the age of 30-35yrs. This could be the
direct result of the undifferentiated breast cells being exposed to carcinogens and DNA
damaging agebts for an extended period of time. If the cancer initiation process has
already begun due to this reason, the full term pregnancy may not have a significant
effect.

Mechanisms of Estrogen Mediated Breast Cancer
Diverse cellular and molecular mechanisms have been shown to mediate estrogen
induced breast cancer progression. Clinical and epidemiological data have led to the
conclusion that endogenous E2 has a critical role in sporadic breast cancer in women.
Two enzyme systems compete for an opportunity to alter the structure of E2 molecules,
but they do so at two different locations, the 2- and 16-carbon positions (Figure 1.1.2.1).
The end products of such reactions are quite different in their biologic roles. Insertion of
a hydroxyl radical at the 2-carbon site produces a neutral molecule while that at the 16carbon location produces a genotoxic molecule, which increases the chances of
spontaneous mutation (269).
Endogenous and exogenous estrogens may initiate and promote breast cancer via
two key mechanisms in susceptible individuals. First, estrogen may also contribute to
mammary carcinogenesis by stimulating the proliferation of a clone of precancerous
cells. There is evidence that estrogen decreases cell cycle transit time, so that DNA
damages and mutations could be passed to the daughter cells before repair (51) perhaps
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due to defective DNA damage checkpoint functions. Cell cycle effects of estrogen have
been studied extensively. These studies show that mitogenic abilities of estrogen are
mostly mediated by genomic functions of estrogen. Estrogen-ER complex induces DNA
synthesis, cell division and production of biologically active proteins such as pS2,
transforming growth factor (TGF), and epidermal growth factor (EGF) that induce cell
growth and differentiation (4). In breast cancer xenograft models using ER positive cell
types, E2 produced pre-malignant and malignant lesions at high frequency compared to
untreated samples (239).
Second, estrogen prevents cell death, especially apoptosis through ER (226),
mitogen activated protein kinase (MAPK) (251), phosphoinositide 3-kinase (PI-3K) (261)
mediated pathways in cell cultures. Data in this dissertation demonstrate the significance
of these types of cell signal pathways in estrogen-induced anti-apoptosis, in response to a
variety of stimuli. Estrogen acts in synergism with anti-apoptotic proteins such as BCL2
(57,210) while abolishing the effects of pro-apoptotic molecules (129 and data in
dissertation). The mitogenic and survival promoting effects of estrogen are further
confirmed by observations that the anti-estrogens or estrogen withdrawal can either block
breast cancer cell proliferation or induce apoptosis (129 and data in the dissertation). In
clinical setting, traditional hormonal therapy for women with breast cancer included
hormone ablation by surgical procedures (oophorectomy, adrenalectomy). Later on, antiestrogens and aromatase inhibitors superseded this strategy (218). Paradoxically,
hormonal therapy with high estrogen doses caused regression of ER positive breast
cancer in post-menopausal women (142). This response was shown to directly correlate
with the duration of the post-menopausal period. This clinical data may suggest that
long-term exposure to very low levels of estrogen might alter the responsiveness of breast
cancer to estrogen therapy. Similar phenomenon was later shown in cell culture systems
using long-term estrogen deprived (LTED) MCF-7 cell variety. Further estrogen induced
apoptosis in these cells when administered in higher doses (252). These observations
clearly provide a clue that the adaptation of cancer cells to lower blood levels of estrogen
might sensitize them to pro-apoptotic effects of estrogen. To extend the breast cancer
treatment in pre- and post-menopausal women, a new regimen of cyclic treatment
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strategies would need to be introduced. Here selective estroigen recptor modulators
(SERMs) or aromatase inhibitors can be used for period of time to sensitize the cancer
cells to apoptotic effects of estrogen (253)

Environmental Estrogenic Compounds and Breast Cancer
In biological regulatory pathways, molecules compete for their receptors. Such
competition among molecules is based upon their structural similarities. However, many
synthetic chemicals not belonging to the family of human hormones actively compete for
receptors for that family. This natural phenomenon is well illustrated by the example of
competition for receptors among estrogens and estrogen mimics such as, pesticides (DDT
and heptachlor), plastic (polycarbonates) breakdown products, PAHs (polycyclic
aromatic hydrocarbons), petroleum byproducts, polystyrene, plant estrogens such as
coumestrol, equol and zearalenone. It has been suggested that these xenoestrogen
molecules may have 3D structures that can fit in the ligand binding site in the steroid
hormone receptor. Therefore, the total burden of estrogen in an individual is constituted
of endogenous and exogenous estrogens. Exposure of previously unexposed women to
xenoestrogens in addition to dietary changes may be partly responsible for higher rates of
breast cancer in oriental females who migrate to the United States. In susceptible
individuals, it is possible that environmental carcinogens and estrogenic compounds
might synergistically enhance the development of breast cancer (78,128,233).

Estrogen Action on Tumor Vascularization
In both tumor growth and metastasis, angiogenesis plays an essential role. Growth
factors, cytokines and extra cellular matrix have been shown to regulate endothelial
function in vivo and in vitro (239). Estrogen action in endothelial cell function also has
been appreciated pertaining to its cardiovascular activities (13). The evidence shows that
estrogen guards against cardiovascular diseases in reproductive years and the protection
wanes as women reach menopause (21,40). Mechanism/s of estrogen function in
vascular component of breast cancer has been proposed, thus estrogen was shown to
increase the expression of vascular endothelial growth factor (VEGF) and other
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angiogenic factors in breast cancer cells (156,290). Paradoxically, E2 inhibited the
growth of breast cancer xenografts (of KPL-1 cells) in nude female mice by abolishing
angiogenesis as well as the level of VEGF production, and the anti-estrogen ICI 182, 780
had opposing effects (156). Whether these cells are ER positive or negative was not
defined. On the other hand, high levels of ER have been shown to inhibit proliferative,
invasive and metastatic potential of a subset of tumor cells in vitro (11). Subsequent to
ERα overexpression, in vivo down-regulation of VEGF and inhibition of vascularization
was observed in tumor xenografts.

Selective Estrogen Receptor Modulators (SERMs)
Receptor mediated estrogenic functions are further modulated by a host of co-regulator
proteins, and the complex nature of these interactions may impart distinctive effects in
different target tissues. Estrogen has multiple desirable effects such as improved bone
density, lipid profile, and benefits for the cardiovascular and central nervous systems.
Unfortunately there are undesired effects including increased breast cancer risk,
stimulation of endometrial hyperplasia and increased risk of venous thrombo-embolism
(VTE). Estrogenic compounds that block or antagonize the effects of estrogen in specific
tissues while retaining some of the beneficial effects in other tissues have shown great
benefits in post-menopausal women as well as women who undergo ovariectomy early in
the life. These pharmacological agents, known as selective estrogen receptor modulators
(SERM) are mainstays in treatment of metastatic breast cancer and have shown promise
as chemo-preventive agents for breast cancer and osteoporosis. SERMs function by
competing for the ER binding to estrogen. Subsequent to ER-SERM interaction,
conformational changes occur in ER thereby blocking ER mediated effects (190).
SERMs posses varying degree of estrogenicity (complete or partial, agonists or
antagonists) depending on the target tissue. This tissue selectivity is well demonstrated
with Tamoxifen, an anti-estrogen used in breast cancer therapy. The rationale for its use
is based on the fact that E2 is a mitogen in ER-expressing breast cancer cells and, this
action can be inhibited by an ER antagonist. Clinical data demonstrated that Tamoxifen
abolished ER dependent breast cancer and promoted increase in bone mineral density
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mimicking the estrogen effect in this tissue (136) as well as in the uterus (124). Receptor
sub-type difference in ER could also influence the pharmacological effects of SERM. It
has been shown that almost all SERMs have antagonistic effect on ERβ where as more
differential effects are seen on ERα (190). Therefore it is possible that differential
expression of ERs could at least partly contribute to the tissue selective effects of SERM.
Structures of some SERMs and their mode of action are shown in Figure 1.1.2.5.

Aromatase Inhibitors
Another approach to anti-estrogen therapy is to lower the amount of estrogen being
produced by the body. In post-menopausal women, estrogen is no longer produced by
the ovaries, but is synthesized from testosterone in the peripheral tissues by a reaction
catalyzed by the enzyme aromatase (40). Aromatase inhibitors block testosterone from
being converted to estrogen thereby limiting the available estrogen level. Recent studies
using third generation aromatase inhibitors (anastrozole, letrozole and exemestane) have
shown better outcome and improved therapeutic ratio over hormonal approaches
(progestins) and over Tamoxifen. These results have led recently to testing of aromatase
inhibitors in the adjuvant setting for postmenopausal patients (218,268).

1.1.3 Apoptosis
Different Ways to Die
Cell proliferation and growth are among the most intensely investigated areas in the field
of cancer research. The notion that programmed cell death (PCD) plays a major role in
the life of multi-cellular organism has gained attention recently and convincing evidence
is accumulating at a fast rate. When a cell of a multi-cellular organism dies by a
mechanism exerted by proteins encoded by the host’s genome, the process can be defined
as physiological cell death. The purpose of this process is to eliminate unwanted host
cells and is important in development and homeostasis, as a defense mechanism and as a
final stage of the aging process. Most genetic or non-genetic changes that deregulate
these cell death programs may underlie the etiology of cancer, autoimmune and
developmental disorders.
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(A)

Modified from
NEJM 346: 340-352
(B)

Figure 1.1.2.5

Modified from Science 29:2380-2381

(A) Structures of SERMs. The structure of estradiol is also shown for comparison
(B) Estrogen binding promotes ER comformational change that permits its spontaneous
dimerization and facilitates the subsequent interaction of the dimer with EREs located within
target genes. Estrogen also facilitates the interaction of the ER with coactivators. An
antagonist-activated ER, on the other hand, interacts preferentially with a corepressor protein.
Evidence suggests that the structure of some SERM–ER complexes favors corepressor
recruitment and that of others favors affinity for known coactivators. The implication of
this model is that SERM activity will be influenced by the relative levels of expression of the
cofactors (corepressors and coactivators) in target cells.
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The term ‘apoptosis’ has been used interchangeably with PCD and has immensely
confused the understanding of regulated cell death. Activation of caspases (aspartate
directed cystein proteases) is the final commitment step to apoptosis in a normal cell (39).
Function of caspases is conserved throughout evolution from nematodes to mammals. In
mammals the process is considerably more complex involving multiple forms of caspases
and their targets. Resulting cell death is characterized by unique morphological features
(described below). Other forms of cell death, which are morphologically and
mechanistically distinct to apoptosis could exist and some of them have been described
(178,255). It may now be the time to note that caspases are not the sole or unique
effectors of cell death programs. In fact, the inhibition of caspases does not prevent the
total cell loss due to apoptotic stimuli (14) or in severely compromised cells by growth
factor withdrawal, metabolic toxins or physiological killers like glucocorticoids (178).
Interestingly, organisms that do not express caspases undergo PCD that does not closely
resemble classical apoptosis (17,91,161,177). Together it is now evident that there are
multiple pathways leading to cell death. Some cells may have the required components
for some pathways but not for others. Also cells may contain inhibitory mechanisms that
rule out a particular program. Moreover, different pathways can co-exist in the same cell
and are switched on by specific stimuli.

Apoptosis
For a tumor biologist defective apoptosis is one of the seven pillars upon which cancer
develops and progresses. Defective cell cycle regulation, growth factor autonomy,
defective senescence, angiogenesis, metastasis and cell invasion are the other six pillars
(73). Apoptosis is a genetically encoded and highly regulated cellular response for a prodeath signal. This results in unique characteristic features such as cytoplasmic shrinkage,
membrane blebbing, nuclear fragmentation, intranucleosomal DNA fragmentation,
phosphatidylserine exposure due to changes in the plasma membrane, and finally
fragmentation into membrane enclosed apoptotic bodies sequestered by macrophages or
other engulfing cells or neighbors (73,143,291).
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Mechanism of Apoptosis
When discussing the central components of apoptosis, it is most appropriate to describe
C. elegans’s genes whose functions led to the discovery of higher eukaryotic
homologues. The core machinery of apoptosis was first discovered in C. elegans and
include Egl-1, Ced-3, Ced-4 and Ced-9 whose mammalian homologues are BH3-only
proteins, caspases, Apaf-1 and BCL2-like proteins respectively (39). The process in the
higher mammals is more complicated than in the worm though the basic makeup of the
mechanism is comparable. Activation of caspases is responsible for the cleavage of vital
components of the cell and it is during this process the characteristic morphological
features of apoptosis (described above) are produced (39).
Major form of apoptosis in vertebrates is mediated by the mitochondria associated
mechanism (102). Caspases are commonly activated by mitochondrial membrane
permeabilization (MMP), or more specifically mitochondrial outer membrane
permeabilization (MOMP) (103), which marks a point of no return from the death
process. MMP leads to the release of proteins normally found in the space between the
inner and outer mitochondrial membranes, such as cytochorme C and apoptosis inducing
factor (AIF) to the cytosol. Though the exact mechanism of MMP is still being debated,
it is clear that local effects on inner and outer mitochondrial membranes could lead to
differences in the membrane potentials. Defective inner transmembrane potential (∆Ψm)
has been clearly observed before, during and after MMP (104). The mitochondrial
respiratory chain produces energy which is stored as an electrochemical gradient or the
∆Ψm, negative inside of about 180-200 mV. This energy source pumps protons (H+) that
drive ATP synthesis. Loss of ∆Ψm is a result of the ion equilibration across the inner
membrane. This could lead to swelling of the matrix as water enters, which can result in
sufficient swelling to break the outer membrane to produce MMP. MMP contributes to
cell death in several different ways. In apoptosis by releasing cytochrome-C, in caspase
independent cell death by releasing factors like AIF (262) and Htra2/Omi (114) and, by
culminating mitochondrial functions that are essential for cell survival such as electron
transport chain (101). Once in the cytosol, cytochrome C contributes to the formation of
the apoptosome (Apaf-1/caspase 9/cytochrome-C) that activates the executer caspases
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(39). A pathophysiological role for MMP is emerging and manifestations of deranged
∆Ψm and release of intermembrane proteins are frequently observed in diseases with
increased cell death (104).
In addition to the mitochondrial-mediated pathway, ligand binding and activation
of the cell surface death receptors has also been implicated in activating caspases.
Activated receptors initiate the recruitment of pro-caspases (eg. pro-caspase 8) and their
adaptor molecules to form the caspase processing unit. This aggregation results in the
transactivation of pro-caspases and consequent cleavage and activation of the down
stream capases and other targets. A cascade of biochemical reactions follows, ensuring
the final fate of the cell. The cell surface receptor cascade also contributes to the
mitochondrial cytochrome – C release through the activation of caspase 8 and its down
stream target BID (39). Finally both mechanisms converge into cleavage and activation
of Caspases 3, 6 and 7 which carry out the proteolysis of death substrates (Figure
1.1.3.1). These pathways are tightly regulated by pro and anti- apoptotic mechanisms
and the balance between them may govern the orderly demise of the cell.

Caspases
Caspases are a well-characterized family of cysteine proteases that are responsible for the
execution of apoptosis. They are also important in other cleavage dependent functions
such as cytokine maturation (10). As the name implies (‘c’ is for cysteine and ‘aspase’ is
for aspartate) these enzymes are able to cleave the substrate after an aspartic acid residue.
Each caspase is initially synthesized as a pro-caspase and requires a cleavage at specific
site (which also is an aspartate) by another caspase to generate active enzyme suggesting
a cascade activity of this family of proteases. Functional apoptotic program in mammals
requires multiple caspases and the contribution of different caspases to different phases of
apoptosis is becoming clearer (39). Currently, 11 human caspases have been identified:
caspase 1-10 and caspase 14. The protein initially named caspase 13 was found to be the
bovine homologue of caspase 4. Caspase 11 and 12 are murine homologues of human
caspase 4 and 5 (73). Caspases are classified in several ways. Most important of those is
the function-based classification where all caspases are fit into three subfamilies i.e.
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Figure 1.1.3.1
General overview of apoptosis
See text for details
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initiators of apoptosis and inflammation (caspase 1, 5, 11), initiators of apoptosis
(caspase 2, 8, 9, 10, 12) and effectors /executors of apoptosis (caspase 3, 6, 7) (73).
Caspases posses very strict substrate specificity. Target substrates can be
subdivided based on their cellular functions i.e. (a) proteins directly involved in
regulation of apoptosis, (b) protein kinases that mediate apoptosis, (c) structural proteins,
(d) proteins required for cellular repair, (e) cell cycle regulatory proteins and (f) proteins
involved in diseases. These are summarized in Table 1.1.3.1 (73). Mouse knock out
studies have contributed enormously to the current knowledge on specific roles of
individual caspases. Phenotypic details of these mice are shown in Table 1.1.3.2..

Regulation of Caspase Activity and Apoptosis
Regulation of caspase activity is implicated in apoptosis and to a lesser extent in cell
proliferation and cellular differentiation. In the latter, limited activation of caspase has
been demonstrated to be essential i.e. proliferation of lymphocytes (8), differentiation of
red blood cells (35) and epidermal cells (87). A family of proteins termed ‘inhibitors of
apoptosis’ (IAP) has been described to play a major role in caspase regulation hence
apoptosis regulation. These proteins function as intrinsic regulators of the caspase
cascade. There are other cellular proteins that modify specific caspases, but IAPs are the
only proteins that can regulate initiator as well as executor caspases.
Several IAPs have been described to date e.g. the first mammalian homologue
neuronal IAP (NIAP), X-chromosome linked IAP (XIAP), Survivin and Livin. They are
characterized by the presence of one or more of baculoviral IAP repeats (BIR). This
domain is important in binding and inactivation of caspases (173). In addition to
apoptosis regulation these proteins have been shown to participate in cell cycle regulation
and receptor mediated cell signaling. Both endogenous (mitochondria mediated) and
exogenous (surface receptor mediated) apoptosis pathways are regulated by IAPs.
Regulatory proteins that bind and suppress the function of IAPs have been
described. Mitochondrial protein Smac, which is released by a similar mechanism as
cyctochrome-C, has been shown to bind to all the IAPs. In addition to Smac, other
mitochondrial and cytoplamic IAP inhibitors have been shown to regulate IAP function.
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Table 1.1.3.1
List of some caspase substrates

Modified from Oncogene 22: 8543

Apoptotic and inflammatory regulators
BID, Caspases, BCL2, BCLxl, XIAP, IkB,
Protein kinases and other signal molecules
Raf, AKT, PP2A, MEKK1, PKC, FAK
Structural proteins

Actin, Lamin A-C, β-catenin,

Repair proteins
PARP, ATM, DNA-PK, Rad51, Rad9
Cell cycle regulators
Rb, p27, p21, Cdc27
Disease related proteins
Huntingtin, ataxin-3, androgen receptor, atropin
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Table 1.1.3.2
Summary of phenotypic characteristics of caspase knockout mice
Modified from Oncogene 22: 8543
Embryonic
lethality

Developmental
defects

Apoptotic defects

Caspase
1

No

No

Defects in inflammatory response
Resistance to septic shock

11

No

No

Defects in lymphocyte apoptosis
Resistance to septic shock
Ischemic brain injury

2

No

Excessive oocyte
generation

Defects in apoptosis induction in oocytes
and lymphocytes
Compensatory activation of other
caspases were reported

3

Yes

Neuronal hyperplasia

Defects in DNA fragmentation
Compensatory activation of other
caspases were reported

8

Yes

Impaired cardiac
muscle formation
Abdominal bleeding

Defects in activation of death receptor
pathway

9

Yes

Neuronal hyperplasia

Defects in apoptosis induction by
genotoxic stress

12

No

No

Defects in endoplasmic reticulum stress
apoptosis
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IAPs can also be substrate targets of caspases, showing another level of apoptosis
regulation. In some instances such cleavage yields a pro-apoptotic molecule that
accelerates the death process where as in other instances it simply represents the final
outcome of apoptosis (76,173).

Endoplasmic Reticulum and Apoptosis
Critical contribution of endoplasmic reticulum (End.Ret.) to apoptosis has been evaluated
recently. The End.Ret. induces stress signaling in response to defective protein folding
through the unfold protein response (UPR) that ultimately drives cell to apoptosis (15).
This phenomenon if termed as ER-stress induced apoptosis. The mechanism by which
ER-stress is coupled to caspase activation was revealed by the characterization of caspase
12 (198). Caspase 12 is specific in its function for ER-stress as has been demonstrated by
null mouse studies (Table 1.1.3.2). In addition to the direct activation of caspase 12,
End.Ret. acts in concert with mitochondria to propagate apoptotic signals. This has been
shown to take place through several pathways. Increased cellular concentration of Ca2+
is frequently observed with End.Ret. stress. This can potentially activate Ca2+ dependent
enzymes such as calcineurin whose down stream effector is the BCL2 family protein
BAD. BAD is dephoshorylated (activated) by this enzyme thereby promoting the
mitochondrial action of BAD (282). Further, increased Ca2+ was shown to directly
activate mitochondrial mediated cytochrome-C release (15). Multi-domain BCL2 family
proteins (pro- as well as anti-apoptotic) have been shown to localize to the ER membrane
(148,153). As in mitochondria, pro-apoptotic BAX like proteins inflict membrane
damage that can be prevented by the expression of BCL2 group. Changes in End.Ret.
membrane cause changes in Ca2+ mobilization that may contribute to the apoptotic
program as described above. Correct protein folding is essential to maintain the
homeostasis of the cell. the End.Ret. acts as the sensor for this mechanism and stops the
metabolic processes until the defect is corrected. It is when the protein folding capacity
of ER is compromised due to a variety of reasons the UPR mediated signal directs the
apoptotic program. It is likely that various apoptotic agents described thus far may also
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have effects on ER. The outcome could then be due to all these programs that work
simultaneously.

BCL2 Family Members and Apoptosis
Apoptosis is highly conserved in multicellular organisms and information gathered from
studying less complex species have been easily translated to more complex counterparts.
Identification of remarkable similarity between the C. elegans ced-9 gene members and
mammalian BCL2 family is the best case in point (5). Several proteins have been
identified to be members of the family subsequent to the discovery of the founder
member, BCL2. BCL2 was described in 1988 as a protein, which is involved in B-cell
lymphomas (277). BCL2 transfected B cells were shown to be resistant towards apoptosis
normally induced in B cells by IL-3 withdrawal: for the first time it was shown that the
pathway toward tumorigenesis depends not only on the ability to escape growth control
but also on the ability to prevent apoptosis. Interestingly, expression of human BCL2 in
C. elegans reduced the amount of programmed cell death suggesting that the mechanism
controlled by BCL2 in human is similar to that in nematodes (278).

Structure and Function of BCL2 Proteins
A hallmark of BCL2 family members is to form hetero or homo dimers, which may
either, be a competition for neutralizing or, result in a synergetic effect. Possession of
one or more of conserved BCL2 homology (BH, 1-4) domains determines the structural
and functional capacities of each member. BCL2 and BAX subfamilies that contain BH
1-3 (Figure 1.1.3.2) show opposing anti-apoptotic and pro-apoptotic effects respectively.
BH3 only proteins compose the third family, which is strictly pro-apoptotic. They may
directly counteract the activities of anti- apoptotic members or induce death via
alternative mechanisms (61,106). However it is clear that their apoptotic function is
solely dependent on the presence of BAX subfamily members (301). At the C-terminus
of most BCL2 and BAX and in certain BH3 only proteins is a hydrophobic region, which
features as a trans-membrane domain important for their membrane targeting (61).
Despite the structural similarities, BCL2 proteins differ in their subcellular localization.
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Figure 1.1.3.2

Modified from Genes and Dev 13: 1899-1911

BCL-2 family members
BCL-2 homology regions (BH1-4) are denoted as is the carboxy-terminal hydrophobic
trans-membrane (TM) domain

32

Among the anti-apoptotic members, BCL2 and BCLxl are found extensively membrane
bound in mitochondrial and ER fractions while BCLw is mainly cytosolic. In the proapoptotic group, BAK is mostly membrane bound and BAX is cytosolic (61). Recent
structural studies have provided insights regarding these differences. In BAX and BCLw,
the C-terminal regions were shown to interact with the groove made up of BH1/2/3 and
therefore, unavailable to interact with membranes (118). The hydrophobic groove is the
target for the BH3 domain of the binding partner and, then there is a need for a
competitive displacement of the C-terminal from the groove. Since BCL2 and BCLxl are
mostly bound to the membrane through the C-terminal transmembrane domain, it is
presumed that their hydrophobic groove is available to bind with interacting BH3
domains.
Pro-apoptotic BAX family members are critical for apoptosis in many cell types.
Double knockouts of these genes have deleterious effects and results in prenatal death,
where as single knockouts show little consequence (170) probably due to functional
redundancy. Upon apoptotic signal, BAX and BAK undergo conformational changes and
form homo-oligomers (193,200). This may require the rearrangement of their BH
domains so that one molecule may act as the donor of the BH3 domain and the other as
the acceptor (the hydrophobic groove). Once activated, BAX and BAK cause membrane
damage, particularly the outer membrane of the mitochondria (influence MMP, described
above). BCL2 and BCLxl over-expression has been shown to neutralize the effects of
BAX and BAK (113,256).
Individual BH3 only proteins appear to have direct and indirect effects on proapoptotic BAX family proteins, contributing to apoptosis induction. BID, upon cleavage
in response to cytotoxicity binds and directly activate BAX (165,169). BAD and BIK
cannot directly activate BAX or BAK but instead binds anti-apoptotic BCL2 preventing
their functions (5,22,165). This information supports the view of two modes of action for
BH3 domains i.e. (1) activating BAX, BAK and (2) sensitizing by occupying the pocket
of anti-apoptotic members. Table 1.1.3.3 summarizes the known functions of some
BCL2 family members.
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Table 1.1.3.3
Summary of functions BCL2 family members

Modified from Science 305: 626-629,
Cell 75: 229, Nat.Gen 16: 358)

Family member

Functions

Anti-apoptotic
BCL2

Deficient mice have defects in renal
development, loss of lymphocytes,
melanocytes and hair pigmentation.
Effects are reversed by BIM deficiency

BCLxl

Knock-out is embryonic lethal.
Massive increase in apoptosis in erythroid and
neuronal cells

BCLw

Deficient mice are viable. Males are impotent

Mcl

Knock-out is embryonic lethal
Pro-apoptotic
(multidomain)

BAX

Deficient mice are viable. Lymphocyte
number is Increased

BAK

Develop normally
BAX/BAK double knockouts die perinatally
due to various developmental defects. Absence
of MMP
BH3 only

BAD

Knockout mice develop normally, with time
display diffuse large B cell lymphoma.

BID

Knockout mice develop myeloproliferative
disorder. Hepatocytes are resistance to Fas
mediated apoptosis.

Noxa

Induced by p53. MEFs are resistant to DNA
damage induced apoptosis when Noxa is
knocked out.

BIM and BOD

Knockout mice show increased lymphoid cells.
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BCL2 family proteins have been shown to participate in other cellular functions in
addition to apoptosis. Cell cycle transit from quiescence to proliferation was blocked
when BCL2 proteins were over-expressed (64) but high levels of BCL2 did not affect the
proliferating rate of continuously growing cultures (61). Most importantly the antiapoptotic and cell cycle effects of BCL2 appear to be genetically separable i.e. cell cycle
effect depends on the amino terminal BH4 domain (121,127). BAD was also shown to
exert a cell cycle effect. BAD expression resulted in failure to block cell cycle
progression in fibroblasts following release from growth arrest conditions. Using
mutation analysis it was shown that BAD requires co-segregation with BCL-xl to exert
this effect (50). Contrary to this, data in this dissertation show that BAD over-expression
blocks cell cycle progression in breast cancer epithelial cells in growth arrest as well as
continuously growing conditions. Further we demonstrate that endogenous BAD has a
regulatory role in cell cycle progression at the level of cyclin D1 transcription.
The BCL2 family proteins are frequent targets of post-translational modification
downstream of both survival and death signal transduction cascades and such
modifications may often dictate their active versus inactive conformation, sub-cellular
localization, and partner proteins (5). The ratio between pro and anti-apoptotic members
helps to determine at least in part the susceptibility to a death signal (140,301).

BAD
BAD (BCL-/BCLxl Associated Death promoter) is an exclusively BH3 domain only
member sharing sequence homology only within the BH3 amphipathic α-helical domain
(Figure 1.1.3.2) in the BCL2 family. It was originally cloned from mouse cDNA by its
ability to bind with BCL2, both in yeast two-hybrid and direct biochemical interactions
(294). Subsequently the human homologue, which is 37 amino acids shorter, was
identified. Both mouse and human counterparts are expressed ubiquitously. BAD
promotes cell death; and it is widely accepted as a pro-apoptotic protein. As for any
other pro-apoptotic BCL2 member (i.e. BID, BIK, BAK and BAX) intact BH3 domain is
important for BAD’s function. It competes for the binding with BCLxl and BCL2 to a
lesser extent, via the BH3 domain thereby affecting the level of heterodimerization of
35

these proteins with BAX or BAK (119,140,204). Possible interactions among BCL2
family members are shown in Figure 1.1.3.3.

Inactivation of BAD
Phosphorylation of BAD on several serine sites found in and out of the BH3 domain
change the effectiveness of BAD as a death-promoting molecule. In the presence of most
survival factors, cells phosphorylate BAD on serine 75 (murine S112) by Ras mediated
ERK/RSK1 pathway (90). Subsequent phosphorylation on serine 99 (murine S136) by
protein kinase B/AKT (70) promotes heterodimerization with 14-3-3 proteins. Such
interaction then facilitates the phosphorylation at serine 118 (murine S155) a site within
the BH3 domain, by PKA (175). Phosphorylation in the BH3 domain weakens the
interaction with BCLxl thereby leading to the cell survival (22,82,119).
Recently another inactivating phosphorylation site, serine 133 (murine S170)
outside the BH3 domain was shown to be important in cytokine induced cell survival
(83), although it remains uncertain which kinase/s is responsible for the phosphorylation.
Deletion of the BH3 domain was shown to completely abolish the pro-apoptotic function
of BAD (140) whereas, point mutations within this domain (leucine 114, aspartate 119;
murine L151 and D156 respectively) have not established any significant corelation with
BAD’s functions (personal communication Dr. A. Kelekar), (3).

Activation of BAD
BAD can also be activated by phosphorylation in response to death signals. To this end
serine 91 (murine S128) has been shown as critical target for phosphorylation by stress
activated JNK signaling pathway. Interestingly the activity of growth factor mediated
signaling failed to inhibit apoptosis induced by BAD S91 phosphorylation, depicting
opposing signaling mechanisms that converge on BAD (80).
Reversible phosphorylation is a key regulatory mechanism in cell survival and
death, and has been shown to regulate the function of BAD. Members of major
eukaryotic serine/threonine phosphatase families have been discovered to dephosphorylate BAD, even though conflicting data for their specificities are obvious.
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Figure 1.1.3.3
Interactions among BCL2 family proteins
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BAD is a target for Ras activated phoshatase (PP1α) as well as calcineurin (PP2B) in
Ca2+ induced apoptosis (19,247). 14-3-3 was shown to actively protect BAD against dephosphorylation by PP2A in vitro implicating that 14-3-3 holds a regulatory role in BAD
de-phosphorylation (55). On the other hand, BCL2 targets BAD for de-phosphorylation
by PP1α. BCL2 possesses the consensus sequence (RIVAF) important for PP1α
interaction and contributes to the formation of a trimolecular complex thereby facilitating
the dephosphoryaltion of BAD by PP1α (20). These mechanisms depict the existence of
regulatory processes that ensure latent status of BAD, which is constitutively expressed
in normal cells.
BAD has been shown to undergo cleavage by caspase 3 resulting in a more potent
pro-apoptotic molecule. This phenomenon was observed in apoptosis caused by
interleukine (IL3) deprivation in murine myeloid precursor cells (59) and in response to
Raloxifene (mixed estrogen agonist/antagonist) in human bladder cell line (147).
Whether BAD is cleaved by proteases other than caspase 3 is not yet clear. In cells that
do not express caspase 3 (e.g. MCF-7 (131)) BAD might not be effectively cleaved.
Notably, in the studies with MCF-7 we have not observed cleaved form/s of BAD in
response to the host of apoptotic stimuli that were used. Several other BCL2 members
are also targets for proteases thus showing that cleavage is another post-translational
modification of this family of proteins. Pro-apoptotic BID undergoes cleavage by
caspase 8 and by granzyme B and promotes mitochondrial release of cytochrome C
(169). In some circumstances anti-apoptotic BCL2 and BCLxl were shown to undergo
cleavage thus forming potent pro-apoptotic molecules (54,58).
The cellular location of BAD is considered to be cytoplasmic since it is devoid of
the membrane anchoring hydrophobic region, which is present in most other BCL2
family members (Figure 1.1.3.2). Upon its interaction with BCLxl or BCL2 that are
anchored onto the mitochondria BAD may be found in the mitochondria. Active survival
mechanisms inflict inhibitory phosphorylation of BAD and promote sequestration of
BAD away from mitochondria. Whether BAD, either phosphorylated or not, has cellular
locations other than the cytoplasm and mitochondria is currently unknown. The
important phosphorylatable residues and domains of BAD are shown in Figure 1.1.3.4.
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Information on phosphorylation of BAD may not be sufficient to explain its role in cell
survival/death process. The large number of signaling pathways that target BAD is
perhaps surprising, but there are indications that more may be discovered soon.
Recently transgenic mouse studies showed that survival factors are less protective
against insults when BAD gene is knocked out. Moreover, the knocked-in
unphosphorylatable BAD did not increase cell death, yet increased the animal’ s
susceptibility for carcinogens, highlighting the impact of BAD phosphorylation on three
serine residues (75, 99 and 118 (murine 112, 136 and 155 respectively) (71,222)). These
studies concluded that BAD is a sensitizing intermediate through which survival factors
set the threshold for apoptosis.

Apoptosis and Beast Cancer
In an adult woman, the cell death in the form of apoptosis and cell proliferation are the
key determinants of the mammary gland homeostasis (155). During the menstrual cycle
apoptosis occurs at varying rates in response to changes in hormone levels in the breast
tissue (220) as well as in the endometrium (66). Similarly, apoptosis plays a key role in
the post-lactational involution subsequent to pregnancy (134). Apoptosis is also
regulated by non-hormonal signals. Changes in apoptotic regulatory mechanisms due to
genetic abnormalities may results in increased cell number, promoting tumor
development and progression. This could promote metastasis by enabling the tumor cells
to survive in the circulation and grow in distant places. Upon detachment from the
basement membrane, epithelial cells undergo apoptosis, which is defined by the term
anoikis (96). In order to metastasize, breast carcinoma cells should overcome anoikis.
Proliferation and apoptosis also determine the growth dynamics of breast carcinomas in
response to a variety of therapeutic measures. Evaluation of treatment-induced changes
in these two parameters contributes to the understanding of the tumor’s response (or
resistance) to the therapy (172). Chemotherapy, radiation therapy as well as
immunotherapy heavily rely on apoptosis to kill breast cancer cells (244) and the changes
that decrease the ability of cells to activate the apoptotic response may play a key role in
resistance to these therapies.
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Studies suggest that once arisen, cancers have a very low threshold for apoptosis, which
may be a consequence to enhanced proliferation. In contrast, a low threshold for
apoptosis may not be a consequence of high rate of proliferation in normal cells e.g.
intestinal epithelium. This very fact is exploited by the cancer therapies that target the
rapidly dividing – more sensitive cancer cell DNA by genotoxic agents. Unfortunately
cancer cells develop resistance for such therapies resulting in a deadly outcome.
Many death and survival genes, which are regulated by extracellular factors, are
involved in apoptosis. There appears to be a critical set of apoptotic mediators regardless
of the initiating agent, which are regulated by various survival mechanisms. These
mechanisms are interconnected so that defects or manipulations in one can cause changes
in the other (discussed in detail in the first part of this chapter). Studies suggest that
anticancer drugs kill susceptible breast cancer cells by inducing the expression of death
receptor ligands such as Fas (FasL), which then bind and activate Fas and death receptor
pathway via caspase 8 (250). Interestingly most breast tumors express FasL as well as
members of TNFα receptor family (29,139). There seem to be controversies in data
regarding such receptor and ligand functions, mostly due to discrepancies in tissue
culture conditions and drug concentrations. Additional studies are needed in breast
cancer cell lines to determine the precise role of this membrane linked, extrinsic
apoptosis pathway. However, the intrinsic (mitochondrial pathway) has been shown to
play an important role in most anticancer drug therapies.
Much of the work on apoptosis and breast cancer has focused on BCL2 and its
family members. BCL2 is important in pathogenesis of B-cell malignancies in human as
the name implies (B-cell Lymphoma/Leukemia 2) but also plays a major role in other
types of cancers. It has been recognized as a proto-oncogene, activation of which leads
to malignancies. BCL2 family proteins play crucial roles in mitochondria-regulated cell
death pathway (Figure 1.1.3.1). Expression of anti-apoptotic BCL2 is increased by E2 in
estrogen responsive MCF-7 (42) and breast cancer tissues (186). Environmental
estrogens are thought to mimic this effect as these agents suppress TNFα induced
apoptosis in ER positive but not in ER negative cells (149). Chemotherapeutic agents
exert their effect also through BCL2 family members. For an instance, paclitaxtel,
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doxorubicin and thiotepa upregulate pro-apoptotic and down regulate anti-apoptotic
members of the BCL2 family (37,186,206). Some of these have been shown to sensitize
MCF-7 cells to apoptosis by phosphorylating and inactivating BCL2 (256) related to
activation of Cdc2, JNK and other kinases. Introduction of anti-BCL2 antibody gene via
a plasmid, enhanced the chemotherapy induced apoptosis in MCF-7 cells and may
represent a novel approach to cancer therapy (213). Microinjection of synthetic BCL2
peptide was shown to reduce the apoptosis induced in renal tubular epithelial calls where
as the BAK and BAX peptides induced apoptosis in otherwise untreated cells (209).
Clinically, increased levels of BAX are correlated with a good response to chemo and
radiotherapy, whereas increased levels of BCL2 and BCLxl are correlated with poor
response (44,171,299).
Protein kinase B (Akt) is particularly important in breast cancer as a signal
intermediate for survival factors such as IGF-1. Dysregulation of Akt signaling as well
as amplification of the Akt gene is a common occurrence in tumors (16,158,257). Akt
phosphorylates and regulates proteins involved in various cellular pathways including
apoptosis. Pro-apoptotic BAD and NFκB are examples for such Akt targets. NFκB is
activated, while BAD is inactivated by Akt (231,295), and both these actions promote
cell survival. The Ras/ERK pathway (one of several Ras oncogene pathways implicated
in cancer) and Akt act in cooperation to induce NFκB activity (231). In MCF-7 cells,
Akt suppressed TNFα induced apoptosis, which also correlated with increased NFκB
activation (26,30). Further, a recent study shows a new model for anti-estrogen
resistance that requires ERα activation by PI-3K and Akt in the absence of estrogen (43).
The caspases have been studied in in vitro cancer models as potential cancer therapeutic
targets owing to their central role in apoptosis (Figure 1.1.3.1). MCF-7 cells, which lack
caspase 3 due to deletion in the caspase 3 gene (131), showed increased sensitivity to
chemotherapeutic agents upon caspase 3 reconstitution (293). Though caspase 3 is
redundant in some settings, it is obviously a key factor towards an efficient apoptotic
program. Therefore further studies may show whether promoting crosstalks between
extrinsic and intrinsic apoptotic pathways (that eventually activate caspase 3 and other
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executor caspases), and upregulation of these caspases are indeed useful strategies of
cancer therapy.

1.2 Hypothesis and Rationale
Estrogens are growth inducers in normal and cancer breast tissue and, are capable of
inhibiting apoptosis in vitro and in animal models. They appear to oppose apoptosis
induced by intracellular (default death signals) as well as extra cellular factors such as
chemotherapeutic agents. The goal of this study is to understand the underlying
mechanisms and dissect specific signal transduction pathways by which E2 exerts antiapoptotic effects in breast cancer cells. Since growth of a malignant tumor is the sum of
cell proliferation and cell death, understanding the factors that regulate both processes is
crucial in understanding the biology of this cancer. It is likely that E2 effects on MCF-7
(and other ER positive breast cancer cells) are more pronounced than in normal breast
epithelial cells. This may be a result of distinct biological changes that occur in cancer
cells during oncogenic transformation.
In response to intracellular and extracellular distress signals, cells enter a
programmed death process called apoptosis. This is executed by death proteases
(caspases) that are tightly regulated in a normal healthy cell. Among the mechanisms
regulating caspase activity, BCL2 family of cytoplasmic proteins takes a centre stage.
Pro- and anti-apoptotic members of this family interact with each other and integrate a
diverse array of upstream survival and death signals and determine the fate of the cell.
Disrupted regulation of apoptosis may be manifested as a variety of disorders.
In the presence of survival factors, BCL2 family member BAD gets phosphorylated on
two serine residues (75 and 99), which are consensus targets for Akt and ERK induced
p90RSK. Phosphorylated BAD is sequestrated in the cytosol by 14-3-3 molecules. Nonphosphorylated BAD binds with anti-apoptotic members of the family such as BCLxl and
BCL2 and abolishes their activity towards cell survival.
PI-3 kinase and its down stream targets mediate survival signals activated by a variety of
agents in MCF-7 and other cell types (221). In addition to its well known down stream
effector Akt, PI-3K also has been shown to have effects on all MAPK pathways (286).
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Activation of Akt and MAPK (specifically ERK) are known to support cell survival and
growth, and their effects in MCF-7 breast cancer cell line are very well documented.
In this study we hypothesize that E2 induces inhibitory phosphorylation of proapoptotic protein BAD at two serine residues through the activation of ERK and PI-3
Kinase pathways, ensuring the survival of ER positive MCF-7 cells, in the presence of a
host of apoptotic inducers.

1.3 Results and Discussion
Figure 1.3.1
E2 effects on H2O2, TNFα and serum withdrawal induced apoptosis are mediated by
PI-3 kinase
Previous work in our laboratory has shown that estrogens decreased cell death and
apoptosis induced in MCF-7 cells by mitogen withdrawal (7). Recent work indicates that
induction of cell growth by E2 in MCF-7 cells may require activity of the PI-3K pathway
(176) and the Ras/ERK pathway (48). Given this background we sought to determine if
PI-3K plays an important role in E2 action with respect to cell growth and apoptosis. In
preliminary experiments we verified that E2 promoted cell survival/growth under low
serum conditions and further established that the PI-3K inhibitor wortmannin inhibited
this effect of E2.
(A) To confirm the requirement of PI-3K activity for the cell survival induced by E2,
MCF-7 cells were treated with E2 in the presence or absence of LY294002, a specific PI3K inhibitor (234) in serum free medium. In the absence of E2, there was significant cell
loss reflected in MTT uptake over a five-day period (n= 4, p<0.05). E2 completely
blocked this decrease and maintained MTT uptake at or above day 1 level. Treatment
with LY294002 abolished the ability of E2 to increase cell numbers as indicated by MTT
uptake (day 2) or maintain cell survival (day 4, 5) and also reduced viability in the
control cultures at day 4 and 5. These results suggest that survival of MCF-7 cells under
conditions of serum withdrawal requires PI-3K activity and that the ability of E2 to
protect cells from death as well as to induce growth is blocked by abrogation of PI-3K
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Figure 1.3.1
E2 effects on H2O2, TNFα and serum withdrawal induced apoptosis are
mediated by PI-3 kinase
(A) MCF-7 cells were treated as indicated and MTT assay was performed
to measure amount of live cells
(B) Apoptosis was induced as indicated and DNA fragmentation was
assayed
(C-D) Western blot demonstrate the PARP cleavage and cytochrome-C
release in response to indicated agents.
(E-G) MCF-7 cells expressing indicated constructs were treated with
various apoptotic agents and DNA fragmentation was assayed.
(H) Western blot demonstrates the exogenous expression of indicated
molecules
(please see the text for detailed experimental conditions)
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activity. MTT results simply demonstrate the amount of live cells present under given
conditions and, in the case of E2, this may reflect the sum of anti-apoptotic and mitogenic
effects.
(B) The above results and prior observations suggest that E2 may decrease apoptosis in
MCF-7 cells. Since TNFα induces apoptosis through activation of caspase8 and, or JNK
activation (39) in a variety of cell types including MCF-7 cells (41,108,267). We treated
MCF-7 cells with TNFα in the presence of E2, 17-α estradiol (an estrogen of low
potency), E2 plus an excess of the specific E2 antagonist, ICI 182,780. TNFα increased
apoptosis as measured by DNA fragmentation by 4-5 fold and E2 was able to reduce this
effect significantly, whereas 17α-estradiol had no protective effect. The presence of an
excess of the E2 antagonist blocked the protective effect of E2 in TNFα treated cells.
(C) Poly (ADP-ribose) polymerase (PARP) cleavage, a well-known late event in the
apoptosis process (86) was induced by TNFα and this cleavage was significantly blocked
by E2 pretreatment.
The reactive oxygen species, H2O2, is known to induce apoptosis in a variety of
cell types including MCF-7 cells (146) and this apoptotic effect is decreased by
pretreatment with E2 or overexpression of BCL2 in a synergistic fashion (210).
Furthermore, E2 and overexpression of BCL2 exhibit additive inhibitory effects on
cleavage of PARP (86) induced by H2O2. In confirmation of this data, we found that E2
pretreatment can block DNA fragmentation as well as PARP cleavage induced by 2 mM
H2O2 (Figure 1.3.1 B and C). Pretreatment with 17-α estradiol had no significant
protective effect against H2O2 suggesting that E2 effects are unlikely to be due to its
potential free radical scavenger function (27).
(D) Apoptotic effects of certain stimuli including those activating the extrinsic pathway
are manifested at least in part via their effects on mitochondrial membrane integrity (82)
(106). Release of cytochrome-C from dysfunctional mitochondria contributes to the
formation of the apoptosome, which ultimately activates the downstream caspase
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pathways (39). Since the results presented in A-C would predict that E2 may preserve
mitochondrial integrity in the presence of apoptotic stimuli, we sought to determine
whether E2 would preserve mitochondrial integrity by assessing cytoplasmic cytochromeC protein level. In untreated or E2 only treated cells, cytoplasmic cytochrome-C was
undetectable. As expected H2O2, TNFα and serum withdrawal increased cytochrome-C
in the cytoplasm. Co-treatment with E2 decreased cytochrome-C release induced by
TNFα to a similar extent as that observed in cells co-treated with serum and TNFα.
Taken together these results suggest that E2 protects cells against apoptosis induced by
TNFα, H2O2 and serum withdrawal (not shown) possibly by maintaining mitochondrial
integrity.
(E, F, G) To establish the role of the PI-3K pathway in E2-induced anti-apoptosis, we
used adenoviral vectors to interfere with operation of this pathway. Cells were
transduced with adenoviral wild type PTEN/MMAC that effectively decreases activity of
the PI-3K pathway by dephosphorylation of PI-3K products (183,199). Over-expression
of PTEN completely blocked the ability of E2 or IGF-1 to prevent apoptosis induced by
serum withdrawal (E), H2O2 (F) and TNFα (G) when compared to adenoviral LacZ
(control) infected cultures. Akt/PKB is a downstream target of PI-3K pathway that
promotes cell survival in a number of cell types (69,81). Similarly the overexpression of
dominant negative Akt (DNAkt) enhanced apoptosis induced by the agents, and
completely reversed the effects of either IGF-1 or E2 on apoptosis prevention. These data
together with data derived using chemical inhibitors strongly suggests that the PI-3K/Akt
pathway is essential for the anti-apoptotic effects of E2 or IGF-1 in MCF-7 cells. We
repeatedly observed that DNA fragmentation (measured by the Cell Death ELISA) in
viral transduced cells was below the levels observed in parental cells (1.8-2.5 vs. 4-5 fold,
compare Figure 1.3.1B and E-G), which lead to an apparent decrease in the magnitude of
apoptosis as measured by the cell death ELISA in the latter.
(H) A Western blot analysis showing the expression of the indicated constructs in MCF-7
cells.
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1.3.2 E2 induced rapid signal pathways impose phosphorylation on BAD
Figure 1.3.2.1
E2 activates the PI-3K/Akt pathway leading to phosphorylation of down stream
targets
The above data strongly suggests that the ability of E2 to decrease apoptosis in MCF-7
cells is at least partly mediated by the PI-3K/Akt pathway. Transient activation
(measured by S473 phosphorylation) of Akt by E2 in MCF-7 cells has been reported
(48,227). Our data suggest that the PI-3K/Akt pathway may need to be activated for a
prolonged period to maintain BAD in an inactivated (phosphorylated) state.
(A) Kinetic behavior of the PI-3K response to E2 was measured. PI-3K activation was
determined by phosphorylation of IRS-1 on S612 by in vitro kinase assay using
immunoprecipitates of the p85 subunit of PI-3K. E2 was able to rapidly activate PI-3K
approximately 3 fold, in growth arrested cells. Similar in magnitude to the activation
elicited by IGF-1.
(B) A detailed time course of Akt catalytic activity in growth arrested MCF-7 cells, was
measured by in vitro kinase assays (n=3) using Akt immunoprecipitates and BAD as the
substrate.
(C) GSK3β is a downstream target of Akt (65). Active GSK3β effectively triggers rapid
cyclin D1 turnover and affects the cell cycle regulation (77). GSK3β activity was
determined by in vitro kinase assay using immunoprecipitates of GSK3β. E2 rapidly and
strongly inhibited GSK3β activity. As expected, another Akt activator IGF-1 also
completely inhibited GSK3β activity. The effect of E2 was sustained for 60 min (our
unpublished data) and such a time course is compatible with the increase in cyclin D1
protein observed 3-4 hrs after E2 addition to quiescent cells (94,95).
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Figure 1.3.2.1
E2 activates the PI-3K/Akt pathway leading to phosphorylation of
down stream targets
(A) In vitro kinase assay with PI-3kinase immunoprecipitataes and IRS-1
as the substrate. Graph represents densitometry values from three
independent experiments
(B) Time course for Akt activation by E2 growth arrested cells. Graph was
obtained from values of three independent experiments
(C) In vitro kinase with GSK3β immunoprecipitataes and MBP as the
substrate
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Figure 1.3.2.2
E2 activates ERKs and down stream target p90RSK
A number of studies reported that E2 rapidly activates ERK1 and 2 in MCF-7 cells (130)
and refs there in) and in a number of other cell types (152,246). However, others failed
to observe E2-mediated ERK activation in MCF-7 cells (47,85,176). E2 induced ERK
activity could be a result of activation of the Ras/Raf signal transduction pathway or may
follow rapid increase in intracellular Ca2+ (130). Previously we had demonstrated that
increased cyclin D1 synthesis in response to estrogens is partly blocked by the MEK1
inhibitor PD98059 and that dominant negative ERK2 partially inhibited the induction of
cell cycle transit by estrogens (7).
(A) Therefore we measured a detailed time course of ERK activation by E2.
E2 rapidly activated ERK with maximum activation of five fold observed within 15 mins
and significant ERK activation was sustained for at least 120 mins (n=4).
(B) Enhancement of ERK activity by E2 was partly blocked by the specific estrogen
antagonist ICI182, 780 and the PI-3K inhibitor LY294002.
(C -D) It is known that p90RSK1 is phosphorylated at S364 and T574 residues by ERKs
leading to its activation (67) and our results on BAD phosphorylation (C) imply that E2
activates p90RSK1. Therefore we directly determined that E2 rapidly activates p90RSK1 by
in vitro kinase assay using immunoprecipitates of p90RSK1 (D) which shows that p90RSK1
is activated within 5min by E2.

Figure 1.3.2.3
Interactions of E2 induced signal pathways
(A panels 1-3) Above results and other recent work (112,286) indicate that there is a
crosstalk between the PI-3K and ERK pathways. We explored this interaction further by
over-expression of adeno viral PTEN. E2 or IGF-1 activated ERKs in control Ad virus
infected cells, PTEN over-expression (approximately 3X over the basal level [panel 3])
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Figure 1.3.2.2
E2 activates ERKs and down stream target p90RSK
(A) Time course of E2 activated ERK measured by in vitro kinase assays (n=4)
(B) Western blot demonstrating phosphorylation of ERKs in response to indicated
agents. (C) In vitro kinase assay (Non radioactive) using immunoprecipitates of p90RSK
and BAD as the substrate. Western blot of the reaction demonstrates phospho
BAD. (D) In vitro kinase assay using with immunoprecipitates of p90RSK and MBP
as the substrate. Expression of p90RSK is shown in a Western blot
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Figure 1.3.2.3
Interactions of E2 induced signal pathways
(A) MCF-7 cells expressing indicated viral vectors were treated with IGF or
E2. Western blot demonstrates the activation of ERK by phoshorylation (panel 1)
In vitro kinase assay with immunoprecipitates of ERK and MBP as the substrate
(panel 2). Level of expression of PTEN is shown in panel 3
(B) Panels 1-2 in vitro kinase assay with immunoprecipitates or Akt and p90RSK
Using BAD as the substrate.
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partly blocked ERK activation observed at 15mins of treatment with these two agonists.
In confirmation of the data using phosphospecific ERK antibodies, PTEN also partly
inhibited ERK2 activity measured by MBP phosphorylation in an in vitro kinase assay
(n=3) (panel 2).
(B panels 1-2) In extracts from similarly treated cells, BAD phosphorylation by Akt and
p90RSK1 were measured in vitro. PTEN over-expression abolished the Akt and p90RSK1
activation. These results suggest that the PI-3K pathway may regulate the ERK response
in addition to the Akt response in MCF-7 cells and provide evidence for cross talk
between these signal pathways in response to E2 or IGF-1, under our experimental
conditions.

Figure 1.3.2.4
E2 induces BAD phosphorylation
(A panels 1-2) BAD is a pro-apoptotic BH3 domain-containing protein (5,106), which
forms heterodimers with BCL2 or BCLxl (59) resulting in cytochrome-C release from
mitochondria. Anti-apoptotic agents like IGF-1 induce BAD phosphorylation at specific
serine residues, and phosphorylated BAD is sequestered away from its site of action in
the mitochondria by binding to cytosolic 14-3-3 proteins (70). Since BAD is
phosphorylated on serine 99 (S99) by Akt (70) and S75 is a target site for p90RSK1 (82),
we ascertained the ability of E2 to induce phosphorylation of BAD at specific residues by
using BAD phosphorylation site mutants as in vitro substrates [note: human S75 and S99
are equivalent to S112 and S136 in mouse]. Clearly E2 or IGF-1 treated cell extracts
were unable to induce phosphorylation of the serine to alanine mutant (S75A) while S99
phosphorylation was enhanced 3-4 fold. Similar specificity was observed when the S99A
BAD mutant was used as the substrate (panel 1). When the double phosphorylation site
mutant (DM) was used as a substrate, only a small fraction of the phosphorylation that
was observed with single mutants was detectable. Multiple immunoreactive bands have
been previously observed when recombinant BAD was used as a substrate (70).
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Figure 1.3.2.4
E2 induces BAD phosphorylation
(A) Panel 1-2, GST-tagged BAD mutants were used as in vitro substrates with
E2 or IGF-1 induced cell lysates. Reactions were Western blotted for
phospho- and total BAD
(B-C) Western blot demonstrating endogenous BAD phosphorylation induced
by indicated agents.
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(B panels 1-2) In vivo BAD phosphorylation was also measured by Western blot
analysis. Following treatment with E2 or IGF-1 for 15mins both S75 and S99
phosphorylations were enhanced (>3 fold) and total BAD levels were unchanged in this
time frame. Panel 2 shows a graph obtained from three independent experiments.
(C) Since our results demonstrated that E2 can induce BAD phosphorylation in vitro and
in vivo and can prevent cell death in response to several stimuli, we studied the possible
changes in phosphorylation status of BAD during apoptosis induction. E2 increased
endogenous BAD phosphorylation at S75 and S99 above the basal level several fold
whereas TNFα and H2O2 decreased it below control level. Co-treatment with E2 and
H2O2 or TNFα restored the BAD phosphorylation to above control levels. Taken
together these data strongly suggest that E2 as well as IGF-1 exert anti-apoptotic actions
partly through phosphorylation and inactivation of the pro-apoptotic BAD protein, and
that phosphorylation of BAD is a consequence of activation of Akt and ERK/p90RSK1

1.3.3 BAD is a key mediator of E2 induced anti-apoptosis in MCF-7 cells
Since the effects of apoptotic agents on decreasing BAD phosphorylation (inactivation)
were largely reversed by E2, BAD inactivation could be a potential non-genomic effect of
E2, which results in cell survival. To better understand the involvement of BAD in cell
death and survival in MCF-7 cells, experimental techniques were used to knock down the
endogenous BAD and over-express wtBAD as well as phosphorylation site mutants of
BAD.

Figure 1.3.3.1
Inhibition of BAD is a critical event in E2 induced anti-apoptosis in MCF-7 cells
(A) MCF-7 cells transduced with antisense oligonucleotides to prevent the translation of
BAD mRNA. The antisense sequences, BAD antisense 1 (BAD As 1) containing the
complementary sequence to the translation initiation codon and BAD antisense 2 (BAD
As 2) containing the complementary sequence to the translation termination codon were
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Figure 1.3.3.1
Inhibition of BAD is a critical event in E2 induced anti-apoptosis in
MCF7 cells
(A) Endogenous BAD was knocked down with anti sense mRNA to BAD.
Western blot demonstrates the efficiency of the reduction of BAD
(B) Quantification of apoptosis by flow cytometry in anti sense mRNA
treated cells in response to TNFα. Change in the apoptotic population due to
TNFα is graphed against each cell population
(C) DNA fragmentation assay to measure apoptosis in response to TNFα in
indicated cell populations
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equally effective in downregulating BAD protein level whereas a scrambled
oligonucleotide corresponding to BAD As1 (control oligo) was not.
(B) Quantification of DNA by flow-cytometry revealed a large reduction of the sub G1
fraction - apoptotic cells (203) in TNFα treated as well as serum-starved (not shown)
cells in BAD As1 and BAD As2 treated, but not in control oligonucleotide treated cells.
E2 did not have an additional effect alone or together with TNFα in anti-sense treated
cells compared to control oligonucleotide treated cells (not shown). Change in apoptosis
due to TNFα was calculated by subtracting sub G1 fraction of untreated from sub G1
fraction of TNFα treated cells for each oligonucleotide treated population. Graph shows
data from three independent experiments. Introduction of BAD As1 or BAD As2
significantly reduced the magnitude of apoptosis in response to TNFα (* = p<0.05), H2O2
and complete serum starvation (not shown).
(C) We next measured DNA fragmentation in oligonucleotide treated cells in the
presence or absence of TNFα. TNFα induced 4-5 fold DNA fragmentation above the
basal level (comparable to Figure 1.3.1) in control oligonucleotide or Lipofectamine
treated cells. BAD As1 drastically reduced this effect (** = p<0.005) and maintained the
DNA fragmentation near the basal level. Similar results were observed using BAD As2
(not shown). This data clearly suggest a critical involvement of BAD in cell survival
and death in response to several agents in MCF-7 breast cancer epithelial cells and agrees
with the reduction in basal BAD phosphorylation induced by TNFα and H2O2 in the
absence of E2 (Figure 1.3.2.4).

Figure 1.3.3.2
Functional serine phosphorylation sites are important for apoptotic function of BAD
(A) To assess the effects on BAD in E2 induced cell survival and consequent changes in
cellular morphology we transiently expressed wild type BAD (wtBAD) and dual
phosphorylation site mutant of BAD (dmBAD) where S75 and S99 are mutated to
unphosphorylatable alanine, together with an EGFP expression vector. Following the
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Figure 1.3.3.2
Functional serine phosphorylation sites are important for apoptotic
function of BAD
(A) Cover slips cultures of MCF-7 cells transfected with wild type or double
phosphorylation site mutant together with EGFP, were treated as indicated.
Nuclei were stained with Hoechst 33342. Number of apoptotic nuclei in response to
treatment is graphed for each cell group.
(B) Similarly treated cells were analyzed with confocal microscope to visualize
cellular changes.
(C) Panel 1-3 Dose response for individual BAD vector in MCF-7 cells.
In response to indicated agents, amount of apoptosis was assayed using DNA
fragmentation, in cells expressing varying amounts of vectors. Panel 4, apoptotic
response in pcDNAtransfected cells.
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Figure 1.3.3.2 continued
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desired treatments, cover-slip cultures were stained with Hoechst 33342 and mounted on
to glass slides. E2 reduced the TNFα induced apoptosis in wtBAD expressing cells by
>50% and importantly had no protective effect in dmBAD expressing cells. Pretreatment of E2 had the same protective effect against TNFα in cells expressing the
control vector pcDNA3 or EGFP alone (not shown). It must be emphasized that the
overexpression of dmBAD did not alter the number of apoptotic nuclei compared to those
in pcDNA3 or EGFP transfected cultures. There is an absolute requirement for TNFα to
induce apoptosis in dmBAD as well as wtBAD expressing cells. The magnitude of
apoptosis observed with cell counting (~ 8-9 fold) is somewhat higher than that observed
with DNA fragmentation ELISA assay (4-5 fold in Figure 1.3.1) in response to TNFα.
Possible explanation for such differences in magnitude may be the fact that only a
fraction of all the cells (i.e. the transfected population) is counted in (A) whereas in
Figure 1.3.1A, DNA fragmentation of the whole population is measured.
(B) Similarly transfected and treated cells were examined by confocal microscopy to
further analyze the cellular morphological changes. TNFα induced cellular shrinkage and
atypical structure of nuclei in MCF-7 cells as has been previously described for fibroblast
(182) and neuronal cells (45). It was difficult to observe the chromatin clumping (typical
for apoptosis) in TNFα treated cells due to shrinkage of the nuclei as opposed to this
feature being readily apparent in paclitaxel treated cells (not shown). Under these
conditions expression of exogenous wtBAD or most importantly, dmBAD (white arrows
in fluorescence images and respective differential interference contrast (DIC) images) did
not enhance basal apoptosis (panel 1 and 4). Treatment with TNFα in wt and dmBAD
transfected cells clearly induced apoptotic changes (panel 2 and 5). While E2 was able to
impede morphological effects of TNFα in wtBAD expressing cells (panel 3) it was
unable to counteract the effects of TNFα in dmBAD expressing cells (panel 6 and 7).
Black arrows in panel 6 and 7 point to the untransfected cells that preserve the normal
morphology. Under these conditions expression of EGFP alone did not induce
morphological changes (white arrows in the insert). These observations further supports
the proposed crucial role of BAD in MCF-7 cells and the critical importance of the two
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specific phosphorylation sites in BAD for the anti-apoptotic effects of E2. It is quite clear
that dmBAD by itself does not induce apoptosis in the absence of TNFα. This suggests
that in these mammary carcinoma cells, there are mechanisms to possibly sequester BAD
away from mitochondria independent of S75 and S99 phosphorylation and binding to 143-3 proteins, thus making dmBAD ineffective as an apoptosis inducer by itself.
(C Panels 1-4) Anti-apoptotic effect of E2 was further evaluated in cells expressing
increasing levels of BAD. MCF-7 cells were transfected with 1/4x, 1/2x, 1x and 2x (x =
regular dose = 0.6ug DNA for 10cm2) of each construct and were treated with TNFα with
or without E2. DNA fragmentation was assayed as described above. E2 reduced
apoptosis by 45-60 percent in the wtBAD expressing cells irrespective of the dose. E2
mediated protection was dampened by the overexpression of dmBAD by 50% or more
(panel 1). A moderate dose dependency in response to dmBAD was observed in TNFα
as well as the E2+TNFα treated cells (panel 3). The values of apoptosis as measured by
ELISA in pcDNA3, wtBAD and dmBAD were unrelated to the dose of DNA. Increasing
doses of wtBAD did not influence the basal apoptosis, TNFα induced apoptosis or the
protection offered by E2 (panel 2). Panel 4 demonstrates the fold induction of apoptosis
in pcDNA3 expressing cells at regular dose of DNA. In wtBAD transfected cells (panels
1 & 2) E2 is able to decrease the apoptosis due to TNFα to the same extent as in
untransfected or pcDNA3 transfected cells (panel 4) by 50-60% when measured by this
method. Taken together this data strongly suggest that BAD is at least partly involved in
E2 induced anti-apoptosis, and dmBAD is not an apoptosis inducer by itself in MCF-7
cells. This reinforces our notion that in these cells, TNFα (and perhaps other apoptotic
stimuli) is able to translocate cytoplasmic BAD to its mitochondrial sites of action
irrespective of phosphorylation at S75 and S99 residues.

Figure 1.3.4
E2 induced BAD phosphorylation requires Ras activated signaling pathways and
Ras function is critical for cell survival of MCF-7 cells
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Figure 1.3.4
E2 induced BAD phosphorylation requires Ras activated signaling
pathways, and Ras function is critical for cell survival of MCF7 cells
(A) Phosphorylation of endogenous BAD in response to indicated agents
demonstrated by Western blot.
(B) Endogenous and exogenous BAD phosphorylation in Ras
transfected cells in the presence and absence of E2. Western blot
demonstrates the expression of endogenous and exogenous Ras in MCF-7 cells
(C) Quantification of apoptosis by counting apoptotic nuclei in indicated
cell populations.
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(A) Previous studies in our laboratory had demonstrated that E2 induced p27kip1
degradation and entry of quiescent MCF-7 cells into the cell cycle requires Ras activity
(6,7,94). Other investigators have demonstrated that E2 rapidly activated Ras in MCF-7
cells (144) and recent work in our laboratory (93) demonstrated that Ras activity is
required for nuclear export and degradation of p27kip1 in response to E2. The
phosphorylation of BAD at S75 and S99 has been proposed to be mediated by
ERK/p90RSK1 and PI-3K/Akt pathways, respectively, in addition to other mechanisms
(82). Given the role of Ras discussed above and the evidence that the PI-3K and ERK
pathways are activated by E2 (as discussed above) we used chemical inhibitors
LY294002 and PD98059 to inhibit these pathways respectively and determined the
effects of these treatments on BAD phosphorylation. E2 induced BAD phosphorylation
on S75 as well as S99 was completely abrogated by LY294002 supporting the idea of
cross talk between the MAPK/p90RSK1 and PI-3K/Akt pathways. Similarly, PD98059
effectively reduced the phosphorylation of BAD at S75 as determined by Western blots,
however the MEK inhibitor had considerably less effect on BAD S99 phosphorylation
(compare E2 vs. PD+E2 on BAD phosphorylation on S99). None of the treatments
changed total BAD levels in this time frame.
(B) Since Ras is a well-known upstream regulator of the PI-3K/Akt and
MEK/ERK/p90RSK1 pathways, we analyzed the effects of inhibition of endogenous Ras
by using dominant negative Ras, RasN17 (DNRas) or selectively activating the
MEK/ERK pathway with RasV12T35S (110) in transient transfection experiments. Flag
tagged BAD was co-transfected with control empty vector, RasN17 or RasV12T35S into
MCF-7 cells. Twenty-four hours after transfection, cells were serum withdrawn for
another 24 hrs and stimulated with E2 for 15mins. BAD phosphorylation was assessed by
Western blotting. Clearly the ability of E2 to increase both S75 and S99 phosphorylation
(panel 1, lane2) of exogenous as well as endogenous BAD was inhibited by RasN17 (lane
4) which by itself did not regulate BAD phosphorylation (lane3). The MEK/ERK
selective activator, RasV12T35S, by itself significantly activated BAD S75
phosphorylation and moderately activated exogenous BAD S99 phosphorylation (lane 5)
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and E2 was able to enhance this effect (lane 6). Taken together the results in (A) and (B)
strongly indicate that the ability of E2 to stimulate BAD phosphorylation and thereby
prevent apoptosis is mediated through Ras activated MEK/ERK and PI-3K/Akt
pathways. Expression of endogenous and exogenous Ras is shown in panel 2.
(C) To directly analyze the apoptotic effects of RasN17 in these cells, we stained nuclei
of Ras transfected cells and studied them by confocal microscopy. Nuclei corresponding
to EGFP expressing cells (co-transfected with Ras or control vector) were counted, and
the graph shows the number of fragmented nuclei as a percentage of total number of
cells. Transient expression of RasN17 induced 7-8 fold apoptosis over 48hr period where
as the expression of RasV12T35S or empty vector had minimum effects on apoptosis
observed in cells co-expressing EGFP. These results demonstrate that Ras function is
required to protect MCF-7 cells from dying even in the presence of growth medium and
that this effect may be mediated at least partly by phosphorylating and inactivating proapoptotic BAD. The observation that E2 induced BAD phosphorylation was abolished by
inactivation of endogenous Ras (B) further highlights the involvement of Ras mediated
pathways in E2 signaling and demonstrates that Ras plays a critical role in the antiapoptosis mediated by E2 in MCF-7 breast cancer cells.
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Chapter 2
BH3 Domain only Protein BAD Regulates Cell Cycle Progression
by Modulating Transcriptional Activities of AP-1

2.1 Introduction
2.1.1 Functional Multiplicity of BAD
BAD is a point where survival signaling pathways interact with the death machinery.
Survival mechanisms inhibit BAD by adding inhibitory phospho groups on to it in order
to prevent its participation in the apoptotic program. Recently a BAD knockout mouse
study (222) showed that survival factors are less protective against apoptotic insults when
the BAD gene is knocked out. Moreover, when the un-phosphorylatable BAD was
“knocked-in” it did not increase cell death, yet increased the animal’ s susceptibility for
carcinogens, highlighting the impact of BAD phosphorylation on three serine residues
(75, 99 and 118 (murine 112, 136 and 155 respectively). Absence of BAD in these
animals also increased the incidence of some tumors like lymphoma. This study
concluded that BAD is a sensitizing intermediate through which survival factors set the
threshold for apoptosis. In the first part of our study (Chapter 1) we studied in detail, the
importance of BAD phosphorylation on two of these critical serine sites, serine 75 and 99
in E2 action as an anti-apoptotic agent. Over-expressed wild type (wt) BAD or dual
phosphorylation site mutant (dm) of BAD did not increase the basal death level in MCF-7
cells. When challenged with apoptotic stimuli, cells expressing wtBAD but not the
dmBAD were remarkably protected against apoptosis by E2. Our study and the BAD
knockout mouse study emphasize the significance of functional phosphorylation sites of
BAD for its role as an apoptotic mediator.
Interestingly BAD was revealed to participate in nutrient metabolism, more
precisely glucose, in mice (68). Here BAD plays an essential role as an assembly factor
for the glucose-metabolizing-enzyme complex at the mitochondrion. BAD deficient
mice displayed an abnormal glucose metabolism result from the inability to form the
enzyme complex. The most exciting finding was that the mice carrying un66

phosphorylatable form of BAD showed a defective glucose metabolism though the
enzyme complex was assembled normally. This finding again suggests that
phosphorylation and/or events secondary to phosphorylation are important for the
“metabolic function” of BAD. Although BAD is believed to be inactive after the
phosphorylation on these serine residues, this “apoptotically inactive” molecule appears
to posses the capacity to perform other tasks.
Growth promoting effects of BAD has also been shown. Chicken embryo
fibroblasts overexpressing wtBAD but not the control vector, increased their proliferation
in the presence of growth factors. This growth promoting effect of BAD was determined
to be dependent on S99 phosphorylation and subsequent 14-3-3 binding (188). All
above findings suggest that BAD requires fully operative phosphorylation sites for its
‘normal function’. It is important to note that the normal function of BAD extends
beyond the apoptosis regulation contributing to the balanced state of cell physiology.
In our preliminary studies a wide spread expression of exogenous BAD was found
in MCF-7 cells. Similarly unphosphorylated and phosphorylated forms of endogenous
BAD were found in the nuclei of proliferating breast cancer cells. These observations
warranted investigation of currently unknown nuclear functions of BAD in breast cancer
cells and the second part of this study focuses on transcriptional effects of BAD on the
cell cycle regulator protein cyclin D1.

2.1.2 Activating Protein (AP-1) Transcription Factor Family
AP-1 is a fundamental or critical class of transcription regulators that sense
environmental information and translates it into expression of specific genes. This family
consists of several basic region leucine zipper (bZIP) domain proteins that homo- or
hetero- dimerize in order to bind with the DNA targets. The basic region harbors the
actual DNA contact region and the leucine zipper enables the formation of the dimer with
the partner molecule (Figure 2.1.2.1). The characteristic feature of AP-1 complexes in
the cell is the heterogeneity in dimer formation. This results from the multiple AP-1
subunits being expressed at the same time. Originally AP-1 was divided into 4 main
groups and sub-groups within them (276) .
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(A)
AP-1 proteins dimerize through hydrophobic
interactions between the amphipathic helices

DNA binding domain (basic region) binds
in major groove on either side of the helix

(B)
fos

AT

jun

TGACCA

F2

jun

TGACNCA

(AP-1/TRE)

(CRE)

7 base pair target genes
cyclin D, Fra

8 base pair target genes
c-jun, ATF3, cyclin A, D

Figure 2.1.2.1
(A) AP-1 proteins homo-or hetero dimerize through leucine zipper domain
in order to bind with the DNA targets. The basic region harbors the DNA
contact region.
(B) Jun/fos heterodimers preferentially bind to 7 base pair AP-1/TRE where as
Jun/ATF-2 binds to 8 base pair CRE
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The first group, AP-1 is composed of jun, fos and fra gene products. Jun proteins
form homo or hetero dimers with other members of the family and bind with high affinity
to 7 base pair TRE (TGA G TCA), which is a phorbol ester 12-O- tetradecanoyl-phorbal13-asetate (TPA) response element (280). Second group, ATF/CREB family proteins is
further divided into two sub families (Table 2.1.2.1) depending on their binding
partnerships. First sub class (ATF1) either homo- or hetero-dimerizes with CREB and
bind with cyclic AMP response element (CRE) which is 1 base pair longer than TRE
(276). Members of the second subclass (ATF2) complex with themselves as well as
members of the first group (AP-1). In addition to the intra-group partnerships, AP-1
family transcription factors tend to interact with other non bZIP proteins (56,258). This
variation in dimer formation could direct the AP-1 factors to promoter elements that
posses very minor resemblance to their consensus sites. This in turn provides AP-1
factors a high level of flexibility in gene regulation potential (276).

AP-1 as a Mediator of Cell Proliferation, Survival and Death
A plethora of physiological and pathological stimuli induce and activate AP-1 proteins.
Studies using cells and mice deficient in individual AP-1 proteins have immensely
contributed to the understanding of their physiological functions. These involve the
control of cell proliferation, growth, neoplastic transformation and apoptosis.
Among growth regulators AP-1 proteins are unusual because they are up regulated in
response to growth as well as stresses that cause cell cycle arrest and/or apoptosis. This
variable behavior might depend on the composition of AP-1 transcription complex, posttranslational modification of individual member as well as other interacting factors. The
clearest data on AP-1 induced apoptosis come from studies on the nervous system.
Continuous c-fos activation was shown to precede neuronal cell death in response to
neurotoxic agents (248). Inhibition of c-jun activity by dominant negative form of c-jun
protected neuronal cells from apoptosis induced by neuronal growth factor (NGF)
withdrawal (205). The activation of c-jun N-terminal Kinase (JNK) has been linked to
induction of cell death in response to a variety of stimuli (25,52). Expression of c-jun
mutant (S63/73A) that cannot be phosphorylated by JNK was employed to effectively
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Table 2.1.2.1
Classification of AP-1 Family Proteins and Their Preferred DNA Elements
Family

Sub Family

Dimmers

Target element/s

AP-1

Jun, Fos, Fra

Homo and hetero

7 base pair TRE

ATF/CREB

CREB and ATF1

Homo and hetero

8 base pair CRE
(cyclic AMP
response element)

ATF2-4, ATF6,
ATFa

Homo and hetero
dimers with
themselves and
Jun & Fos

8 base pair CRE
(cyclic AMP
response element)

C/EBP

Hetero dimers
with both above
families

Data not available

Maf

Hetero dimers
with both above
families

Data not available
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block apoptosis (as effectively as JNK inhibitors) thereby showing the direct relationship
between JNK and c-jun (92,238). Interestingly, there are other reports on physiological
and pathological conditions in nervous system where JNK activation precedes c-jun
phosphorylation without inducing apoptosis (238). Genotoxic stress induced apoptosis in
response to UV radiation depends heavily on c-jun activation as demonstrated using c-jun
and JNK null mouse fibroblast that are resistant to UV induced apoptosis (273).
However in vivo observations show that AP-1 proteins in fact have protective roles in
normal development. C-jun deficient embryos show massive liver apoptosis, which
might result in lethality (28). Additionally JNK or c-jun independent apoptosis has been
described in response to TNFα (174).
Different mechanisms of AP-1 actions described above may not be mutually
exclusive. Various stimuli could induce subsets of AP-1 regulated genes that support cell
proliferation or survival, or in extreme conditions cell death. AP-1 proteins, mostly
members of Jun group, control cell growth through their ability to regulate the expression
and function of cell cycle regulators such as cyclin D1, p53, p21(cip1/waf1), p19(ARF)
and p16. For instance, c-Jun is able to positively regulate cell proliferation through the
repression of tumor suppressor gene expression and function, and induction of cyclin D1
transcription (237,238,288). JunB, which upregulates cell cycle inhibitory proteins and
represses cyclin D1 (207), antagonizes these actions. Table 2.1.2.2 summarizes the
effects of Jun family proteins on cell cycle regulators.

Cyclin D1 Regulation by AP-1
Cyclin D1 protein regulates cell cycle progression at the G1 to S transition. It interacts
with the respective kinase partner, cyclin dependent kinase 4 (CDK4) to enhance its
action. This eventually results in the phosphorylation and inactivation of the
retinoblastoma protein (Rb), which is inhibitory for the cell division (60). The human
cyclin D1 gene promoter sequence contains an AP-1 element at position -954 (9).
Accordingly, several AP-1 proteins have been shown to bind to this site. C-jun was
shown to induce cyclin D1 transcription in transient expression studies (9) and
phosphomimicking mutations of c-jun (mutation of serine 63 and serine 73 of c-jun to
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Table 2.1.2.2
Effects of Jun Proteins on AP-1 Target Genes Involved in Cell Proliferation
Modified from Shaulian and Karin Oncogene 20: 2390-2400
Gene

C-jun

JunB

JunD

Cyclin D
p16
p19
p53 and p21

Up
Down
Down

Down
Up
Down

Down
-
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negatively charged residues) further increased the extent of cyclin D transcription. Fos
group members cooperate with c-jun to induce cyclin D levels (36). Whether cyclin D is
the major mediator of AP-1 induced cell cycle progression was addressed by transducing
cyclin D into c-jun -/- cells. Only 30% of the DNA synthesis was restored by cyclin D
introduction (288). This demonstrates that AP-1 may require other effectors in addition
to cyclin D to mediate its cell cycle effects (288).

p53 Regulation by AP-1
Another important c-jun target is p53, a negative regulator of cell proliferation. C-jun
negatively regulates p53 expression and its down stream functions. In c-jun-/- cells a
high basal p53 level was observed and this was reversed by stable expression of c-jun
(235). A direct relationship between these two players was established when an AP-1
response element was found in the p53 promoter. Interestingly, while c-jun is a potent
activator when bound to its target sites, on p53 it appears to repress the transcription of
the gene. Most importantly deletion of p53 abrogated all cell cycle defects in c-jun -/cells (235). DNA damage by UV exposure often results in c-jun phosphorylation by JNK
(discussed above). On the other hand DNA damage triggers the up regulation of p53,
which acts via p21 (cell cycle inhibitor) to suppress cell cycle progression. It is well
established that c-jun activation in this situation leads to the down regulation of p53 and
relief the growth arrest. Eventually cells may resume growth or may undergo apoptosis
depending on the extent of DNA damage. In some settings cells require c-jun to undergo
apoptosis in response to UV damage (discussed above) and in another setting, cells
increased sensitivity to UV induced apoptosis in the absence of c-jun (235). These may
appear contradictory yet may very well represent the true complexity of endogenous
system that is governed by complex mechanisms mediated by multifaceted AP-1
proteins.
Another AP-1 induced and apoptosis related molecule is FasL. DNA damaging
agents, which also activate JNK, such as UV, induce FasL. AP-1 directly induced FasL
transcription through the AP-1 binding element found in FasL promoter (138).
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Regulation of c-jun by Phosphorylation
C-jun is an immediate early gene whose expression level increases within an hour of the
stimulation. However, its transcriptional functions depend on post-translational
modifications, namely phosphorylation. About 8 phosphorylation sites of c-jun have
been described to date. Two N-terminal serine sites, 63 and 73 are largely accepted as
the most critical residues pertaining to the transactivation function. These are the wellknown targets of JNK (164) as well as ERK1 and 2 (196,197). Upon phosphorylation of
these residues conformational changes occur in c-jun to facilitate DNA binding (196 and
refs therein). Subsequently, several more residues were identified (threonine 231, 239,
serine 243 and 249), that are proximal to the DNA binding domain. Phosphorylation of
these residues abolished c-jun and DNA binding (34). In vivo and in vitro studies
identified kinases such as GSK3, CK2, ERK1 and ERK2 as responsible (196 and refs
therein). This information suggested that c-jun activation requires phosphorylation of Nterminal S63 and S73 and dephosphorylation of C-terminal residues. Recently two more
threonine residues (91 and 93) were identified whose phosphorylation was essential for
the dephosphorylation of C-terminal residues. It is the conformational change that results
from T91 and 93 phosphorylation that facilitates the accesses of phosphatases to the Cterminal sites (196). Currently the exact kinase/s that are responsible for the
phosphorylation of these residues are not known. Evidence suggests that kinase other
than JNK can be involved since in JNK null mice these sites were found to be
phosphorylated (196). Collectively, it is conceivable that full activation of c-jun may
require N-terminal serine phosphorylation by JNK (also by ERK), and C-terminal
dephosphorylation which depends on the phosphorylation of two N-terminal threonine
residues whose in vivo upstream kinase/s are remained to be identified.

Estrogen Action on Cyclin D1 Promoter Depends on AP-1
Estrogens are responsible for the proliferation of normal mammary epithelial and
development and progression of breast cancer (Chapter 1.1 Introduction). They act in
early G1 phase of the cell cycle, and both steroidal and non-steroidal anti-estrogens arrest
estrogen-dependent cell lines in the G1 phase (12,33,272). Previous studies suggest that
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cyclin D1 may be involved in mediating the estrogen induced cell proliferation in normal
and malignant breast epithelial cells (24,94,264). Cyclin D1 deficient mouse are
defective in estrogen responsive proliferation of breast epithelium during pregnancy
(242). Estrogens induce MCF-7 cell cycle in conditions where mitogen activated protein
kinases are continuously inhibited. This correlated with the expression of cyclin D1 as
well as the phosphorylation of retinoblastoma protein (12). Interestingly the increased
expression of cyclin D1 upon over-expression of estrogen receptor (ER) has been noted
(38). However, no ERE-related sequence has been found in the proximal cyclin D1
promoter (115).
In addition to the classical ERE dependent mechanism, an alternative pathway of
ER action has been described. Here ER induces certain promoters that express AP-1
protein binding sites (49,99,159). The fundamental facts of ER action on AP-1/TRE
elements have been demonstrated by several groups. First, DNA binding of Jun and Fos
is needed for ER action, and ER appears to increase the intrinsic transcriptional activity
of these factors when bound to DNA (160,212,274). Next, SERMs are able to active
AP-1 target genes through binding to ERβ (187,284). Genetic dissection of ERα has
provided important clues on the mechanism of ER action on AP-1. Activation functions
(AF-1/AF-2) dependent and independent pathways of ERα have been shown to be
important in estrogen induced AP-1 activities. In the AF dependent pathway, estrogenER actions points to the function of co-activator molecules. ER was shown to interact
specifically with Jun proteins, but not with the Fos family proteins (271). Contrary to
this, isolated ligand binding domain (LBD) of ER was shown unable to directly bind with
AP-1 proteins, though it was able to induce AP-1 action (285). Hence the most
conceivable mechanism could be that, ER may bind with the Jun/Fos recruited coactivator complex, which includes p300, CBP as well as p160 (100,271). ER could join
the already recruited activator complex at the AP-1 binding sites and trigger the coactivator function to a higher state (160). This triggering model may explain how
estrogen-ER could have promoter specific effects i.e. the promoters that carry more
elements in addition to ERE may be more responsive to estrogen.
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In the AF independent pathway, which has been observed in response to SERMs, ER
appears to activate AP-1 mediated transcription without directly participating in the AP-1
complex. The finding that ER interacts with transcriptional co-repressors such as N-CoR
only in the presence of SERM (284) suggests that ER may sequester N-coR and
associated repressors namely histone deacytalases (HDACs) away from the AP-1 binding
sites. This may allow the histone acetylases (HAT) in the co-activator complex (recruited
by Jun/Fos) to act without inhibition (98). It is interesting to note that neither of these
models requires ER and AP-1 protein direct interactions, or the DNA Binding domain
(DBD) of ER.
The mechanism by which estrogen induces cyclin D1 in ERα positive cells has
been linked to AP-1 responsive sites in the promoter. Among the known cyclin D1
promoter elements are AP-1/TRE and CRE (115) both of which can be activated by AP-1
protein binding (Figure 2.1.2.1B). The minimal cis-acting element in the cyclin D1
promoter responsive to estrogen was mapped to position –96 to –26, which contains a
putative CRE (232). Mutations in this region caused complete loss of estrogen
responsiveness suggesting an essential role of this element in mediating estrogen effect.
Agreeing with the previous observations (276), c-jun and ATF-2 heterodimers were
shown to be the most effective transcription factor in CRE transcription, and estrogen
enhanced that basal effect. Remarkably, isolated CRE sequence of the cyclin D1
promoter was unable to induce transcription when removed from its natural environment
(232). This shows the importance of adjacent DNA for CRE function. They may play a
role in recruitment of co-regulators to the CRE site. This study also shows that the DNA
binding domain and the activation function of ER are important for cyclin D1 induction
by estrogen.
Estrogen induces c-jun expression as well as phosphorylation in an ER dependent
manner (217,232), but does not affect expression of ATF-2 (232). Therefore, it is likely
that ER plays a dual role in cyclin D1 expression (i) through activating c-jun and (ii)
acting as a co-activator for c-jun/ATF-2 dimer thereby increasing CRE transcriptional
activity (Figure 2.1.2.2).
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Figure 2.1.2.2
Possible estrogen/ER and AP-1 actions at the cyclin D1 promoter
Estrogen induces c-jun expression as well as its phosphorylation in an ER dependent
manner. ER plays a dual role in cyclin D1 expression (1) through activating c-jun
and (2) acting as a co-activator for c-jun/ATF-2 dimer thereby increasing CRE
transcriptional activity
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2.2 Hypothesis and Rationale
Preliminary observations that over-expressed wild type BAD inhibits cell cycle transit in
MCF-7 cells led us to investigate likely cell cycle regulatory effects of this molecule.
Additionally, BAD abolished the activating protein response element (AP-1/TRE
luciferase) activation in MCF-7 and T47D cells. E2 induced cell cycle progression
depends on cyclin D1 and associated kinases as has been previously shown. Since cyclin
D1 carries an active AP-1/TRE element at position –953 of its promoter, we hypothesized
that BAD induced cell cycle block may result at least partly from an inhibitory action on
this DNA element.
Presence of endogenous as well as exogenous BAD in the nucleus raised our
curiosity as how this translocation could occur since BAD does not contain a typical
nuclear localization signal (NLS), and there is no information about another molecule
that may bind to BAD and facilitate its nuclear import. BAD co-immunoprecipitated
with c-jun, which is a critical regulator of AP-1 functions, in the nuclear extract. This
observation led to the hypothesis that BAD binds with c-jun as a normal regulatory
mechanism and when present in extra amount further sequesters c-jun away from its site
of action. Binding with c-jun and/or a subsequent step may facilitate BAD’s
translocation to the nucleus.
Further we hypothesize that the functional phosphorylation sites, S75 and S99 are
important for this transcriptional regulatory function of BAD since the dual
phosphorylation site mutant was incapable of inducing cell cycle block and the AP-1
transactivation.

2.3 Results and Discussion
Figure 2.3.1
Over expression of BH3 only BAD impedes the breast cancer cell growth in culture
Two plasmid constructs (Flag-BAD and GFP-BAD) were used to over-express BAD in
MCF-7 as well as T47D, breast cancer cells. Presence of high amount of BAD did not
kill these cells as we had observed previously (in contrast to the observations made by
other authors). However BAD appeared to slow down the rate of their proliferation as
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Figure 2.3.1
Over expression of BAD impedes the breast cancer cell growth in culture
(A) MCF-7 cells were transfected with the indicated constructs, growth arrested and
induced with E2. DNA profile was assayed. Percent of S/G2 fraction is shown in the
graph. (B) Cells expressing the indicated BAD constructs and cells where
endogenous BAD was knockdown (siRNA) were kept in complete growth medium
for indicated times and S/G2 fraction was analyzed (n=2). (C -D) Cells transfected
and treated as in (A) were lysed and whole cell lysate was used for Western blot
analysis. (E) asynchronous cells were transfected as indicated and Western blot
analysis was done as in (C).
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judged by visual observation of transfected cells. This observation prompted us to
investigate whether in addition to its pro-apoptotic functions BAD plays any role in cell
cycle progression.
(A) MCF-7 cells were growth arrested at G1/G0 using anti-estrogen ICI182, 780 in low
serum conditions for 48 hours and induced with 5-10 nM E2 for 17 hours. As measure of
cell cycle progression, the DNA profile was analyzed by flow cytometry. Change in
S/G2 fraction is graphed for various treatment conditions (n=4). BAD over-expression
remarkably blocked E2 induced G1-S progression compared to control vector
(pcDNA3.1) transfected or untrasfected cells (p<0.005). Similar inhibitory effect was
observed in BAD transfected cells in response to 5% FBS (not shown). Since known
BAD’s functions are mostly tied to its phosphorylation status, we questioned whether a
relationship would exist between cell cycle regulatory function of BAD and its
phosphorylation level. Dual phosphorylation site mutant (dmBAD) was expressed,
growth arrested and treated as described above. Expression of dmBAD did not block the
effect of E2 on cell cycle progression as cells entered S phase in the presence of E2 as
much as observed in pcDNA3.1 transfected cells.
(B) Cells expressing indicated constructs or cells in which endogenous BAD was
inhibited by siRNA, were maintained in complete growth medium. At indicated times
cells were harvested and DNA profile was analyzed. Mean values S/G2 fraction from
two independent experiments with duplicates for each treatment are shown. Marked
reduction of S/G2 fraction by wild type BAD was observed at 48 hr post-transfection.
Increased S/G2 fraction is apparent with BAD siRNA at 72 hr post-transfection, which
clearly correlated with the expression levels of cyclin D1 (E).
(C) E2 induced MCF-7 cell cycle progression through the regulation of cyclin D1 protein
(12,95,263). Since BAD abolished E2 induced cell cycle progression, a logical question
is whether BAD influences the cyclin D1 level in these cells. Cells were transfected and
growth arrested as described in (A) and treated with E2 or 5% serum for indicated
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periods. Whole cell extracts were obtained and Western blot analyses were performed
using the indicated antibodies. E2 up-regulated cyclin D1 in control cells, but not in
wtBAD over-expressing cells. Further, wtBAD over-expression completely prevented
serum from inducing cyclin D. These results indicate that cell cycle regulation by BAD
requires its phosphorylation at S75 and S99.
(D) Various BAD mutant constructs were used to further elaborate involvement of BAD
phosphorylation sites and other domains. Single phosphorylation site mutants of BAD
had variable effects, where as the dmBAD was completely incapable of inhibiting cyclin
D response in E2 induced cells. This data suggests the involvement of functional
phosphorylation sites in BAD’s action. Further strengthening this idea, a BH3 domain
mutant of BAD, which cannot interact with other BCL2 family members, but carries
intact S75 and S99 phosphorylation sites, had an inhibitory effect similar to the wild type
protein.
(E) Asynchronous MCF-7 cells were transfected with siRNA for endogenous BAD. At
indicated times, cells were harvested and total protein was used in Western blot analysis.
siRNA treatment at 72 hrs inhibited endogenous BAD >75%. Marked increase in cyclin
D1 protein expression was observed that correlated with the reduction in BAD
expression. Data presented is a representative of two independent experiments with
comparable results.
In (C-D) exogenous BAD expression is assayed by Western blot analysis using anti-Flag
antibody, and as a protein loading control, levels of actin are shown. Western blots
shown are representatives of at least three experiments performed, with comparable
results.
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Figure 2.3.2
Cyclin D1 is a Transcriptional Target for BAD
Reduced cyclin D1 protein levels in response to an excess amount of BAD could reflect
the destabilization of the protein and/or negative regulation of its transcription and/or
translation. Therefore, effects of BAD on cyclin D1 transcription and translation were
assayed.
(A -B) Metabolic labeling of cultures with 35(S) labeled methionine was used to detect
efficiency of cyclin D1 synthesis in asynchronous (A) as well as synchronous (G1
arrested) MCF-7 cultures in response to E2 (B). Cells were transfected and treated as
indicated. Cyclin D1 immunoprecipitates of each sample were resolved in SDS-PAGE.
Gels were dried and autoradiograms were obtained. Over-expression of wtBAD
significantly reduced the basal cyclin D1 synthesis in asynchronous cells. E2 enhanced
the synthesis of cyclin D1 in growth-arrested cells in a time dependent manner. BAD
completely abolished this effect at 2 hrs and partially at 4 hrs, demonstrating the ability to
negatively regulate cyclin D1 production in response to a specific mitogenic stimuli as
well as in complete growth medium. Neither BAD nor control vector expression
influenced the newly synthesized CDK4 and CDK2 as observed with the
immunoprecipitates of these proteins (B bottom panels). Amount of actin in the input is
shown as a protein control for the immunoprecipitions. Autoradiograms shown are the
representatives of at least three independent experiments with comparable results.
(C) A cyclin D1 promoter construct was used to demonstrate the involvement of BAD in
cyclin D1 transcription control. Over-expression of BAD significantly reduced the
promoter activity measured by the activity of the luciferase gene product (* p<0.0001);
whereas expression of dmBAD had no negative effect on the cyclin D1 promoter. BAD
induced inactivation of the cyclin D1 promoter is comparable to that was observed with
synchrony of cells at G1 phase. Data presented is from three independent experiments
with duplicates for each sample, with comparable results.
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Figure 2.3.2
Cyclin D1 is a transcriptional target of BAD
(A) Proliferating cultures of MCF-7 cells transfected with the indicated constructs
were labeled with 35(S) methionine for 2 hrs. Total cyclin D1 was
immnoprecipitated and newly synthesized cyclin D1 is shown in the radiogram.
Bottom panel shows a Western blot of actin as the loading control. (B) MCF-7
cells expressing indicated constructs were growth arrested and induced with E2
(10nM). 35(S) methionine was added simultaneously with E2. Newly synthesized
cyclin D1, CDK2 and CDK4 were detected by immunoprecipitation as described
in (A). (C) Cyclin D1 promoter luciferase was co-expressed in MCF-7 cells with
indicated constructs (1/3 of the total DNA content). Luciferase activity was
assayed 36 hr post-transfection. (D) Cyclin D1 promoter mutants (CRE single and
CRE/TRE double mutant) were used as in (C) (n=2). (E) TRE mutant of cyclin D1
promoter was used with or without BAD as in (C) (n=2).
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(D) Mutant constructs of cyclin D1, CRE single mutant (CRE mut) and CRE and AP1/TRE double mutant (CRE/TRE mut) preceding luciferase gene were expressed in
MCF-7 cells with indicated BAD constructs or control plasmid. Relative luciferase
activity 36 hr post trasnfection is shown in the graph. wtBAD failed to inactivate the
cyclin D1 promoter when CRE is mutated, showing that BAD’s influence is essentially
mediated through the CRE rather than AP-1/TRE in this natural promoter. This
observation agrees with the suggested critical role for CRE in cyclin D1 transcription in
breast cancer cell.
(E) A TRE mutant of cyclin D1 promoter (intact CRE) was used to further demonstrate
the specificity of BAD’s effect. wtBAD significantly inhibited the reporter activity
showing supporting the data in (D). Data from two independent experiments with
duplicated samples are shown in the graph.

Figure 2.3.3
BAD targets AP-1/TRE Element through Association with AP-1 Proteins
The evidence in Figure 2.3.1 argues that BAD can decrease synthesis of cyclin D1 as
well as the activity of its promoter. The promoter of cyclin D is highly complex and is
composed of various regulatory elements such as AP-1/TRE, SP-1 and CRE. Importance
of AP-1/TRE and CRE for the cyclin D promoter activity in response to various agents
has been shown previously (115). Data in Figure 2.3.2D-E shows the importance of
these elements in the context of BAD regulatory effects. Influence of BAD on the
activation of these elements was further determined.
(A-B) MCF-7 cells were transfected with AP-1/TRE luciferase with wtBAD or empty
vector pcDNA3. In asynchronous (A) and synchronous (G1) (B) cells the basal and E2
induced AP-1/TRE activation was measured. Over expression of BAD significantly (*p<
0.05) reduced the basal AP-1/TRE transactivation in asynchronous as well as
synchronous cells. E2 induced reporter activation (# p< 0.005) was significantly inhibited
by the expression of BAD, but not the empty vector. Comparable data was obtained
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Figure 2.3.3
BAD targets AP-1/TRE element through association of the AP-1 proteins
(A-B) MCF-7 cells were transfected with AP-1/TRE (control vector tetracycline
response element) luciferase with wtBAD or empty vector pcDNA3. In asynchronous
(A) and synchronous (B) cells the AP-1/TRE activation was measured. (C) EMSA
assay with indicated nuclear extracts. Panel on the right shows the efficiency of c-jun
and BAD depletions from the nuclear extract.
(D) EMSA assay with indicated nuclear extracts. Labeled NFκB sequence was used
as a control probe. Bottom panel shows the expression of BAD in indicated nuclear
extracts. (E) Western blot shows c-jun in immunoprecipitates of BAD from indicated
MCF-7 extracts and E2F levles were determined by WB. (F) Western blot shows cjun in immunoprecipitates of indicated proteins from MCF-7 nuclear extracts. (G)
Immunoprecipitates of BAD or Flag from the indicated nuclear extracts were
Western blotted for phosphorylated and unphosphorylated c-jun. (H) Western blot
demonstrating expression of the indicated proteins in the nuclear extract input for (G)
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using T47D breast cancer cells (data not shown). As a control, tetracycline response
element luciferase (TRE) was used. BAD or pcDNA3 co-expression did not influence
the activity of this reporter (A), which does not carry an AP-1 element.
(C) To further assess the BAD influence on AP-1/TRE element, radio labeled element
sequence (TGACTCA) was used as a probe in an electro mobility shift (EMSA) assay.
Indicated nuclear extracts were incubated with the probe and change in nuclear factor
binding was evaluated. Depletion of BAD from the nuclear extract (lane 3) reduced the
nuclear extract and labeled probe binding to the same extent as did by c-jun depletion
(lane 5). BCL2 depletion on the other hand, did not reduce the interaction between probe
and nuclear factors. Western blot shows the efficiency of depletion of the indicated
molecules from the nuclear extract.
(D) In the presence of exogenous BAD (lane 3) the nuclear factor and probe binding was
significantly lower than that of control extract (lane 2). This effect was reversed when
endogenous BAD was inhibited by BAD anti-sense mRNA (lane 4). Labeled sequence
of NFκB was used as a control. Over-expression or diminution of BAD did not influence
nuclear factors and NFκB binding. Western blot shows the expression of endogenous
and exogenous BAD in the nuclear extracts.
Data from EMSA studies show that depletion of BAD from the nuclear extract or
expression of exogenous BAD had inhibitory effects on AP-1/TRE element - nuclear
factor binding. This could suggest that BAD interacts with AP-1/TRE element DNA
binding factors in the nuclear extract and that when BAD is depleted from the latter,
those that are bound to BAD are also removed. When in excess, BAD might compete
with DNA binding by these factors and therefore decrease binding of nuclear factors to
DNA. This is conceivable since a reduction of probe binding instead a supershift (which
would indicate BAD/nuclear factor binding to DNA), which is observed in response to
BAD over-expression (lane 3)
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(E-F) Given that c-jun is one of the nuclear proteins that bind to the AP-1/TRE element
we sought to determine whether BAD interacts with c-jun. Furthermore, c-jun has also
been shown to participate in AP-1 dependent cyclin D transcription (9). Endogenous
BAD complexed with c-jun in the nucleus but not in the cytoplasm of proliferating MCF7 cells (E). BCL2 did not complex with c-jun under this condition demonstrating the
specificity of BAD and c-jun interaction (F). E2F1 was measured as a nuclear marker.
(G) Gene transactivation functions of c-jun are regulated by its phosphorylation status.
We determined whether BAD and c-jun interaction depends on the phosphorylation of cjun by measuring active c-jun (N-terminal phosphorylation at S63 and S73) levels in
BAD immunoprecipitates. Unphosphorylated but not the phosphorylated form of c-jun
was immunoprecipitated by endogenous as well as exogenous BAD in the nuclear
extracts.
(H) Nuclear extract used in (G) was assayed for the expression of various proteins by
Western blot. In BAD overexpressing cells, amount of c-jun phosphorylation is
markedly low compared to control as well as BAD antisense treated cells. Of note,
expression of total c-jun was not changed either by increasing or reducing the level of
BAD in these cells.

Figure 2.3.4
BAD Inhibits c-jun Phosphorylation via Signal Transduction Mechanisms
(A) The data above suggests that BAD could prevent AP-1/TRE activation via its effects
on c-jun. In normal conditions BAD appears to physically interact with unphosphorylated c-jun in the nucleus (Figure 2.3.3.G). Since the over-expression of BAD
completely abolished c-jun phosphorylation, we questioned, in addition to physical
interaction, which is evident under normal conditions with endogenous BAD, whether
exogenous BAD could prevent c-jun being phosphorylated by upstream kinases, thereby
inhibiting its DNA binding. Activities of c-jun kinases were assayed by their
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Figure 2.3.4
BAD inhibits c-jun phosphorylation via signal transduction mechanisms
(A) MCF-7 transfected with indicated constructs were growth arrested and
treated with E2 or serum for 3 hrs. Western blot demonstrates the expression of
indicated proteins in the whole cell extract.
(B) AP-1/TRE luciferase (1/4 of total DNA) was expressed in MCF-7 with
indicated constructs. BAD or empty vector pcDNA3 was introduced at 1:1 ratio
with the signaling intermediates.
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phosphorylation status. In serum treated cells, active JNK induced c-jun
phosphorylation, and this was inhibited by BAD over-expression (lanes 2 and 5).
E2 increased c-jun phosphorylation considerably through a mechanism, which
appears to be JNK-independent. This correlated with the phosphorylation of ERK1 and
2, which was also inhibited by BAD overexpression (lanes 3 and 6). This suggests that cjun activation in response to serum and E2 are mediated by different mechanisms. BAD
when overexpressed at least partly inhibit these mechanisms.
Expression of dmBAD did not have any effect on the signal molecules despite its
comparable expression to wtBAD (lanes 7-9) suggesting an important role for
phosphorylation in the signal transducing effects of BAD. The Western blot shown is a
representative of more than three independent experiments with comparable results.
(B) To further clarify the effects of BAD on extra cellular signal activated protein
kinases, activated constructs of signal intermediates were used. Expression of activated
form of MEK1 and RasV12S35T mutant, both if which specifically activate ERK1 and 2
increased the AP-1 luciferase activity 8-10 fold above basal level. This effect is
significantly reduced by the co-expression of BAD (at 1:1 ratio). The activity elicited by
MyrAKT (constitutively activated) was not interfered by BAD, indicating a specific
effect of BAD on the Ras/ERK signal pathway. Data from two independent experiments
with two replicates per each treatment was used in the graph. Since our data shows that
BAD can inhibit MEK1 mediated AP-1 activation, BAD might regulate ERK activation
or downstream events which result in c-jun phosphorylation.

Figure 2.3.5
Inhibitory Effects of Over-expressed BAD on AP-1/TRE Functions Depend on its
Phosphorylation
Cellular functions of BAD are mostly regulated by its level of phosphorylation i.e. hypophosphorylated BAD is apoptotically more active than the hyper-phosphorylated form.
We wondered whether the nuclear effects of BAD would also depend on its
phosphorylation, if so, to what extent. Phosphorylation site mutant BAD (dmBAD),
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Figure 2.3.5
Inhibitory effects of over-expressed BAD on AP-1/TRE functions are
dependent on its phosphorylation status
(A) Extracts of proliferating MCF-7 and T47D cells were analyzed by Western blots
to detect phosphorylated and total BAD.
(B) Fluorescent images of immuno histochemically stained MCF-7 cells.
Endogenous BAD (phosorylated and unphoshorylated) is shown in green and nuclei
in blue. Images were merged to demonstrate BAD localization in the nucleus.
(C) Nuclear extracts of MCF-7 cells expressing various BAD mutants were
analyzed by Western blot. Phosphorylation of BAD is detected using anti phospho
BAD S75 and S99 antibodies.
(D) Indicated BAD mutants were co-expressed with AP-1/TRE luciferase reporter
(1/4 of total DNA) in MCF-7 cells. Luciferase activity was assayed 36hr post
transfection.
(E) EMSA with indicated nuclear extracts and labeled AP-1/TRE element.
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when expressed to the same level could not negatively regulate the cell cycle or the
cyclin D1 protein level, as did the wtBAD (Figure 2.3.1A, C).
(A) Expression pattern of phosphorylated form of BAD was assayed in various cell
compartments. In proliferating breast cancer cells (MCF-7 and T47D), endogenous BAD
is present in nucleus and cytoplasm as shown by Western blots. However the level of
phosphorylated forms in the nucleus is very low compared to cytoplasm. This suggests
that the endogenous AP-1/TRE regulatory effects of BAD may not depend on its
phosphorylation status. Similarly only the unphosphorylated endogenous BAD could
complex with c-jun in the nucleus (Figure 2.3.3 F and data not shown). Data shown is a
representative of three independent experiments with similar results.
(B) Immuno histochemistry technique was used to detect endogenous BAD in MCF-7
cells. Cells were incubated with BAD antibodies (total, phos BAD S75 and phos BAD
S99) followed by fluorescent conjugated secondary antibodies (green). Nuclei were
stained with Hoechst 33342 (blue). Images were merged to demonstrate localization of
BAD in the nucleus. Images shown are the representatives of three or more experiments
with comparable data.
Considering our observation that excess amount of wt BAD but not dmBAD plays
a negative role on AP-1/TRE mediated cell cycle progression, it is reasonable to
speculate that the inhibitory effect of BAD is phosphorylation dependent. If so, overexpressed BAD should be found in the nucleus.
(C) Various BAD mutants were expressed and nuclear extracts were assayed. Almost all
the mutants expressed were present in the nucleus and they are phosphorylated on
relevant residues in contrast to endogenous BAD. Note: Flag-BAD vectors give rise to
two immunoreactive bands in Western blots. One at 23-25kD and the other around 3035kD. The discrepancy between nuclear distributions of phosphorylated endogenous and
exogenous BAD may relate to nuclear accumulation and dephosphorylation of these
molecules in addition to other factors.
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(D-E) Whether the dormant role of dmBAD in cell cycle regulation is a reflection of its
effect on AP-1/TRE element was the next question we addressed. AP-1/TRE luciferase
reporter assay (D) as well as the EMSA (E) clearly shows the neutral effects of dmBAD
on this element. Graph in (D) was obtained from at least three independent experiments.
Autoradiogram in (E) is a representative of two experiments with comparable results.
Collectively the data in this study show that (1) BAD has a regulatory role on AP1/TRE mediated expression of cyclin D1. This effect is mediated by physical interaction
with c-jun and possible sequestration from its site of action or from its activating kinases.
It is very likely that, this effect of BAD at least partly contributes to the equilibrium state
of AP-1/TRE functions, which are diverse and complex. (2) When present in excess,
BAD appears to intervene with the c-jun phosphorylation (Figure 2.3.4A), in addition to
physical interaction (Figure 2.3.3G). Both of these effects could contribute to the
observed inhibitory effect. Interestingly the effects of exogenous BAD appear to depend
on the functional phosphorylation sites.
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Chapter 3
General Discussion
The study presented in this dissertation was designed to (1) dissect E2 mediated signal
mechanisms that are important for cell survival and, (2) analyze the significance of proapoptotic, BH3 domain only protein BAD in breast cancer cell survival and proliferation,
in an in vitro breast cancer model.

3.1 Importance of BAD in E2 Mediated Anti-Apoptosis
E2 is known to support cell survival though paradoxical induction of apoptosis has also
been described. E2 induced apoptosis in rat embryo fibroblasts stably transfected with
ERα (163) and MCF-7 cells transfected with Raf-1. In the latter the mechanisms were
postulated to be mediated by ERβ and AP-1 transcription factors (89). Estrogen activated
p38MAPK leading to apoptosis of ERα -stably transfected Hela cells (298). In addition, the
response of neurons to estrogen depends on the ER subtype of the cells; ERβ undergo
apoptosis, whereas cells with ERα are protected from apoptosis. Although the
mechanisms underlying the effect of estrogen are not clear, apoptosis mediated by ERβ
requires FasL (201). Decreased proliferation and increased apoptosis are associated with
Jurkat T lymphocytes exposed to estrogen and decreased BCL2 proteins as well as
mRNA levels were observed during this estrogen effect (133). Similarly, the thymic
atrophy due to thymocyte apoptosis has been described with estrogen treatment (202). In
bone tissue, estrogen inhibits bone resorption by directly inducing apoptosis of the boneresorbing osteoclasts in an ER dependent manner (137). Furthermore, induction of
apoptotic gene E9 was observed in estrogen-treated E8CASS (a MCF7 variant) cells and
the apoptotic action of estrogen was suggested to be mediated by this molecule (266).
MCF-7 cells that were long-term estrogen deprived underwent apoptosis in contrast to
their survival response to estrogen under normal conditions (252) (discussed in 1.1.2
Introduction). Analogous findings have been reported in the prostate cancer cell line that
is normally growth stimulated by androgenic compounds (135), and may constitute the
common biologic response in hormone-responsive tissues. Cell death induced by
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estrogen is not a common phenomenon and occurs in a few cell types in contrast to the
survival benefits that are observed with many cell types.
Most of E2’s actions on cell survival or death have been attributed to gene
regulation. Emerging evidence for non-genomic actions of E2 prompted us to examine
the signaling mechanisms of E2 with respect to regulation of cell survival in MCF-7
breast cancer cells. Our study shows that E2 significantly reduces apoptosis induced by
TNFα, H2O2 and serum withdrawal utilizing signal transduction pathways that lead to
phosphorylation and inactivation of pro-apoptotic protein BAD.
E2 effects on BCL2 family members have been described previously: in cells
where survival is promoted, E2 increased mRNA (210) and protein levels of antiapoptotic BCL2 (57,79) or down regulated pro-apoptotic BAK protein (166). In contrast
to regulation of BCL2 and BAK at the transcriptional level, we find that E2 rapidly
induces phosphorylation of BAD at two serine residues (75 and 99) without altering BAD
protein levels suggestive of activation of non-genomic signal pathways. Given the fact
that pro-apoptotic effects of BAD are decreased by phosphorylation and consequent
sequestration by 14-3-3 proteins (82), we determined whether E2 induced
phosphorylation of BAD is important for the anti-apoptotic functions of E2.
Apoptotic stimuli used in this study increased cytochrome-C level in the
cytoplasm and co-treatment with E2 reduced this effect concomitant with improved cell
survival. This is suggestive of the restoration of mitochondrial integrity at least to some
degree in E2-treated cells and may account for anti-apoptotic effects of E2. In cells
treated with TNFα and H2O2 the extent of BAD phosphorylation was lower than that
observed in control cultures implicating the activation of BAD by these apoptotic stimuli.
Accelerated dephosphorylation of BAD as well as the reduced phosphorylation as a result
of deactivated survival signals can be presumed under these conditions. Estrogen
treatment in this context restored phosphorylation to control levels. These experiments
along with those demonstrating that E2 prevents apoptosis in cells over-expressing wild
type but not the double phosphorylation site mutant (S75A/S99A) of BAD suggest that
BAD phosphorylation has a central role in apoptosis of MCF-7 cells. Remarkably the
expression of BAD (S75A/S99A) did not cause apoptosis by itself, suggesting that in
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addition to phospho-serine mediated cytosolic 14-3-3 binding there may be other
mechanisms to sequester BAD away from mitochondria. These mechanisms effectively
inactivating BAD are counteracted by apoptotic stimuli like TNFα.
Importance of BAD in MCF-7 cells was confirmed by using antisense
oligonucleotides to suppress BAD protein translation and analyzing the effects of
selected apoptotic agents on MCF-7 cell survival. Diminution of BAD in MCF-7 cells
significantly reduced the extent of apoptosis induced by TNFα suggesting that BAD
phosphorylation/inactivation has a central role in apoptosis of MCF-7 cells in response to
stimuli like TNFα. Agents such as TNFα and H2O2 have been shown to exert mixed
effects on BAD protein levels and phosphorylation. TNFα increased phosphorylation of
BAD through PI3-K pathway in neutrophils (63), and in HeLa cells (208) where cell
survival rather than the cell death was promoted by this agent. TNFα also induced the
production of more potent truncated form of BAD in a caspase 3 dependent manner
leading to apoptosis in Jurkat cells (59). Similarly H2O2 but not superoxide anion (O2–)
has been shown to increase BAD protein levels in cardiomyocytes leading to apoptosis
(281). Serum starvation may modulate activity of BAD and other apoptosis regulators
and such effects may be reversed by addition of growth factors or by manipulating signal
transduction pathways (23,295). Recent evidence from BAD knockout mice suggests
that BAD may have an important pro-apoptotic role in cell types such as the mammary
tissue. Importance of BAD was especially underscored in apoptosis that occurs in the
absence of growth factors (222) much like the importance of BAD inactivation in the
response to E2 which is a well known growth factor to breast cancer cells. However it is
also evident that BAD concentration or phosphorylation status could not be used to
define survival or apoptosis in other cells such as PC12 cells (184).

Estradiol Signals Through Two Interacting Pathways in its Anti-apoptotic Action
In addition to genomic actions, E2 has been known to exert rapid, likely nongenomic
actions both in the whole animal and in cultured cells (126,226,265). Previously, we had
observed that estrogens require the function of the Ras, mitogen-activated protein kinase
kinase (MEK)1 and extracellular signal-regulated kinase (ERK) pathway to induce G1/S
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phase transition (7) and elicit down-regulation of the Cdk2 inhibitor p27kip1 (93). Given
that E2 is now known to activate kinase-regulated signal transduction pathways in MCF7
and other cells (192) we have examined potential nongenomic pathways involved in its
anti-apoptotic actions, in particular the PI-3K/Akt and ERK/RSK pathways, which
mediate BAD inactivation and favors cell survival. The ability of dominant negative Akt
or PTEN to reverse the protective effects of E2 suggests an essential role for signal
transduction through PI-3K/Akt in E2 action in protecting cells from apoptosis. Akt is a
known oncogene and is overexpressed in breast cancer cell lines when compared to
untransformed breast epithelial cells, as well as in breast cancer specimens where the
majority of cells are ER positive (261). Given the importance of PI-3K/Akt pathway to
anti-apoptotic action of E2 (194,211) we examined aspects of this pathway, which might
influence cell survival. Our results clearly indicate that PI-3K/Akt has a critical role in E2
action as a survival agent and a rapid and sustained activation of Akt in response to E2
was found. Prolonged activity of Akt may be required to maintain BAD phosphorylation
at S99 as well as to maintain GSK3β in the inactive state. Active GSK3β is required to
stabilize cyclin D1 (77) and increased cyclin D1 protein is a characteristic response to E2
in MCF-7 and other estrogen responsive cell (94 and refs there in). E2 signaling has also
been shown to closely associate with the PI-3K/Akt pathway in vascular endothelial cells
(120) and ERα is phosphorylated by activation of the PI-3K/Akt pathway in MCF-7 cells
in the absence of E2 (43,259). These studies provide insights to growth factor induced
signal mechanisms that couple and converge the genomic and non-genomic effects of
ER.
In addition to Akt-mediated signaling, our data demonstrate that E2 may also
signal through Ras/ERK/p90RSK pathway since endogenous and exogenous BAD were
effectively phosphorylated at S75, a well-known ERK/p90RSK phosphorylation site (82)
in E2-treated cells. Our studies with activating and inactivating Ras mutants provides
strong evidence for this line of argument and show that BAD S75 is a target of Rasmediated MEK/ERK activity. We could directly demonstrate that E2 is able to activate
p90RSK1 a downstream target of ERK1 and 2 (31,300). Although the ability of E2 to
activate ERK remains controversial (47,176,251), ERK activation seems to be important
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in the apoptotic response (90,241) perhaps through the regulation of BAD
phosphorylation via p90RSK. The prolonged activation of ERK in contrast to transient
activation reported by others (192) may be important to maintain the phosphorylation and
inactivation of BAD, acting in concert with Akt. It is also possible that BAD can be
phosphorylated by kinases other than Akt and p90RSK and that such phosphorylations
may enhance or diminish the pro-apoptotic capacity of BAD (80,111,150,175). The two
signaling pathways that are described here may function as separate entities or interact in
order to mediate E2 effects. Previous studies have shown that Ras/ERK and PI-3K/Akt
exhibit regulatory cross-talk (240,286,297). Regulation of ERK by E2 through the PI3K/Akt pathway has not been previously reported to our knowledge. Using both
biological and chemical inhibitors we found that PI-3K may be required not only for E2,
but also, for IGF-1 induced ERK activation as well as BAD phosphorylation at S75, a
likely target of the ERK/p90RSK pathway. Therefore it is likely that E2 regulates ERK
activation, in part, through PI-3K pathway and our data suggest that E2 regulates a step
upstream of PI-3K, possibly Ras function (230).
Expression of dominant negative Ras (RasN17) on the other hand interfered with E2induced BAD phosphorylation on both serine residues without affecting the basal BAD
phosphorylation or protein levels supporting the notion that E2 regulates PI-3K through
Ras (145). However we cannot exclude the possibility that E2 may regulate another
kinase, which can phosphorylate BAD on S99. The ability of RasN17 to induce
apoptosis in proliferating cells suggests that Ras plays a critical role in preventing
apoptosis in MCF-7 cells as observed in other cells (289). Since 3’4’5’ or 3’4’PI
phosphates regulate a variety of signal pathways such as Akt and PDK that could lead to
modulation of Ras/Raf/ERK pathway (221), non genomic signaling by E2 may be quite
complex (168). Furthermore, activation of PI-3K by E2 through a direct interaction of the
p85 subunit with ERα was reported in human vascular endothelial cells (243) and MCF-7
cells (261). Clearly further studies are needed to delineate signaling mechanisms and
their interactions in the perspective of estradiol’s anti-apoptotic and cell cycle effects.
The non-genomic signaling of E2 is postulated to be mediated by membrane
associated ER (141) and this hypothesis is further supported by the recent demonstrations
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of membrane located ERα in MCF-7 and other cell types (185,216). According to these
authors the fraction of plasma membrane bound ERα ranged from 3-20% of the total in
MCF-7 cells. Agreeing with this notion our data shows that E2 induced rapid ERK
phosphorylation and the protective effects against apoptotic agents was substantially
blocked by the anti-estrogen ICI 182,780.

3.2 BAD Has a Role in Cell Cycle Regulation
Above findings clearly define a role for BAD in E2 mediated anti-apoptosis in breast
cancer cells. To extend our knowledge on BAD regulated cell survival and function to
another level, we assayed the transcriptional activities of BAD in the context of cell cycle
progression as our data indicated the presence of BAD in the nucleus.
Cell proliferation and apoptosis are two major pathways that are important for the growth
and development of a multi-cellular organism. The natural interdependency of these two
key mechanisms keeps the tissue mass to a balance i.e. increased proliferation
consequently triggers cell death through apoptosis and other programmed cell death
process, where as reduced cell death is of no significance in the absence of enhanced
proliferation. Just as cell death shapes tissue remodeling or development, cell death also
maintains the course and nature of the immune response. Lymphocytes mediated,
immune-directed programmed cell death provides a mechanism that is the basis for selfversus non-self discrimination and potentially the immnuorecognition and removal of
damaged or cancerous cells (discussed in 1.1.1 Introduction).
Multitasking proteins such as Ras, Myc and c-Jun have been shown to participate
in both cell proliferation and cell death and, our data strongly indicate a novel role for
BAD in cell cycle control.

The concentration of BAD modulates cell cycle progression
Under normal conditions, BAD is phosphorylated on S75 and S99 and bound by the 143-3 like molecules a measure to reduce the sensitivity to apoptotic signals (71).
However, there is a substantial amount of unphosphorylated BAD in a normal cell and
the cytoplasm appears to be the major location for both forms. Known pro-apoptotic
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functions of BAD mostly occur in the cytosol or the mitochondria. Localization of
endogenous BAD in breast cancer cell nuclei strongly suggests an existence of a
currently unknown reserve of this molecule. When present in an excess amount, BAD
prevented cell cycle progression in response to growth factors and E2, where as, BAD
knockdown enhanced the cell cycle entry in a time dependent manner. A negative
regulation on cell cycle by BAD is plausible in an unstimulated cell, since the reduction
of BAD improves the progression from G1 to S. The observation that was made with
BAD over-expression could then be an exaggerated or magnified effect of this normal
endogenous effect of the molecule.
Similar phenomenon has been observed with BCL2 and BCLxl in malignant as
well as normal epithelial cells. When overexpressed, BCL2 arrests cells in G0/G1 phase
and this effect depends on the amino terminal BH4 domain (121). Interestingly in a
variety of epithelial cell types, endogenous BCL2 was shown to localize to the
chromosomes of mitotic nuclei (180). This pattern of BCL2 expression can be
considered as an indicative of its special role in cell proliferation. Mutation of the
conserved tyrosine residue within the BH4 domain of BCL2 and the equivalent residue
Y22 in BCLxl eliminated their ability to delay S phase entry with out affecting the ability
to inhibit apoptosis (125), leading to the conclusion that anti-apoptosis functions of these
proteins can be genetically separated from their cell cycle function. The cell cycle delay
effect of BCL2 and BCLxl has been measured as lengthened time to reach S phase from
quiescence, which results from enhanced G0 arrest or delayed transit through G0-G1
(132). The reduction in S/G2 fraction concomitant with increased G1/G0 fraction in
BAD overexpresing, asynchronously growing cells suggests the retardation of the
passage from the latter. MCF-7 cells that are synchronized in G1 by anti-estrogen and
low serum readily progress into S phase upon mitogenic stimuli (94) and this response is
also reduced due to excess amounts of BAD. Studies are underway to clearly identify the
exact location of the cell cycle arrest due to BAD under these conditions. Extending our
analysis to normal mammary epithelial cells, we should be able to evaluate the
physiological relevance of BAD’s effect on the cell cycle.
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Cyclin D1 regulation by BAD through AP-1 proteins and their binding elements
Regulation of cell cycle in ER+ breast cancer cell line MCF-7 has been extensively
studied and the information on mitogenic effects of E2 and other agents on these and
other breast cancer cells are abundant (7,94,95). Cyclin D1 plays an important role at the
G1 to S transition upon a mitogenic signal (94) and has been implicated as a
diagnostic/prognostic marker of breast cancer. Transcription of the cyclin D1 gene and
the stability of the gene product are tightly regulated hence the function of the molecule.
Members of the AP-1 transcription factor family, particularly c-Jun has been shown to be
involved in the transcription control of cyclin D1 (discussed in Chapter 2.1). c-Jun
induces mRNA and protein levels of cyclin D1 in response to proliferative signals, which
correlates with the progression of cell cycle. However, cell cycle defects in c-Jun-/- cells
were only partially (30%) relieved by the overexpression of cyclin D1 suggesting that
cyclin D1 is not the only target of c-Jun in this context.
An increased expression of cyclin D1 protein was observed in the BAD knockdown
conditions, which correlates with the increased G1 to S transition. An inhibitory effect
on the cell cycle by BAD or its down stream target/s could have been revoked by the
decrease in BAD, resulting in this proliferative effect. This hypothesis is further
supported by the overexpression studies where an increased amount of BAD abolished
the cyclin D1 level in response to mitogens. De novo synthesis of cyclin D1 was
markedly reduced under excess BAD expression, which is likely to contribute to the
above observation. However, BAD’s influence on the stability of the cyclin D1 protein
cannot be ruled out.
The signal axis of c-Jun activation to cyclin D1 expression in MCF-7 cells
appears to be obliterated by BAD as phosphorylation dependent activation of c-Jun and
the upstream kinases were significantly reduced by its overexpression. BAD’s influence
on signaling pathways have not been described to date and require further studies. The
activity change without a change in the expression levels strongly suggests a nongenomic action on these signal molecules by the excessive amount of BAD, presumably
accelerated dephosphorylation. As per our hypothesis that the effects of exogenous BAD
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are the exaggerated endogenous effects, the site of this action of BAD needs to be
identified.
BAD’s influence on c-Jun appears to be two fold since in addition to inhibiting its
phosphorylation, BAD binds to the unphosphorylated or transcriptionally inactive c-jun
in the nucleus. Additional to the known regulatory mechanisms that govern the level of
phospho c-jun available for gene transactivation, BAD may function as a sequestering
entity for c-jun thereby preventing it being phosphorylated by activating kinases, under
normal conditions. The significance of this interaction can be postulated by the extent of
BAD bound c-jun in the nucleus, which is approximately 10-15%.
Regulation of cyclin D1 in response to E2 is mediated through AP-1 binding DNA
elements such as TRE and CRE (Chapter 2.1 Introduction). Our studies exploring the
transcriptional and translational control of cyclin D1 in BAD over-expressing cells show
that BAD indeed negatively regulates the de novo synthesis of cyclin D1and the cyclin
D1 promoter activation. Assay of cyclin D1 promoter –reporter constructs where AP-1
protein binding sites have been mutated (structure of cyclin D1 promoter, Figure
2.1.2.1B) shows that BAD’s influence is essentially mediated through the CRE rather
than AP-1/TRE in this natural promoter, an observation that agrees with the suggested
critical role for CRE in cyclin D1 transcription in breast cancer cell (115).
Using minimal AP-1 binding DNA sequences in electro mobility shift (EMSA)
and reporter assays, we further evaluated the inhibitory effects of BAD on AP-1 protein
and DNA interaction. Level of BAD in the cell appears to influence the efficiency of this
interaction in MCF-7 cells. When present in an excessive amounts BAD significantly
reduces this interaction to an extent that is comparable to the dominant negative c-Jun.
An increased protein-DNA interaction was observed under BAD knockdown condition in
vivo and in vitro. Further, BAD over-expression markedly reduced the TRE-luciferase
activity, which is dependent on the direct interaction of AP-1 nuclear factors and TRE
sequence, in asynchronous and E2 induced cells. Availability of active AP-1 transcription
factors is critical to ensure proper DNA binding in above conditions and inhibition or
unavailability of these factors can be presumed, to result in decreased DNA biding when
BAD is present. This data clearly suggest a regulatory role for BAD, upstream to AP-1
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protein and DNA interaction, an effect that is physiologically manifested by the cell cycle
blockade.

BAD Effects on Cell Cycle regulation depend on its phosphorylation
It is well established that, when phosphorylated on two serine residues (S75 and S99)
BAD is inactive in respective to its pro-apoptotic function (Chapter 1.1.3 Introduction).
Agreeably, our data demonstrate the dephosphorylation-mediated activation of BAD by
apoptotic agents and the restoration of BAD phosphorylation during the E2 induced antiapoptosis. Further, BAD dephosphorylation (achieved by knocking in the
unphosphorylatable mutant of BAD) sensitized mice and mouse embryonic fibroblasts to
apoptosis induced by death receptor signaling and DNA-damaging agents (71).
Together, all above information suggest that BAD phosphorylation and
dephosphorylation specifically regulate the response to apoptotic stimuli that involve
mitochondrial dysfunction and, phosphorylated BAD is a critical mediator of survival
signals in cells. Our data also suggest the critical involvement of BAD phosphorylation
in its cell cycle regulatory function. Analogous to this, mono-site or multi-site
phosphorylation of BCL2 in the flexible loop region enhanced its anti-apoptotic effect
and retarded the cell cycle progression (74). This observation refutes the previous notion
that the anti-apoptotic and cell cycle effects of BCL2 are functionally separable (121),
and links these two functions through phosphorylation. Similarly, in the case of BAD,
pro-apoptotic and cell cycle regulatory effects appear to be linked by phosphorylation.
In the context of nuclear/transcriptional effect, the phosphorylated or
‘apoptotically inactive BAD’ is notably important. The cell cycle block subsequent to the
regulatory effects on AP-1 functions, observed with wild type BAD were not readily
visible with the dual phosphorylation site mutant of BAD in which S75 and S99 are
mutated to unphosphorylatable alanine despite the satisfactory expression level of this
molecule. In contrast, BH3 domain mutant, which retains the intact S75 and S99 was as
effective as the wild type BAD. A step subsequent to BAD phosphorylation is likely to
mediate another AP-1 regulatory effect in addition to BAD mediated binding and
sequestration of c-Jun in the nucleus. Inactivation of c-Jun activating kinases by the
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overexpressed, phosphorylatable wild type BAD but not the phosphorylation site mutant
supports the supposition that BAD regulates these signal transduction pathways in a
phosphorylation dependent manner.
At least 50% of the cells that overexpressed wild type BAD were able to counter
apoptotic stimuli when E2 was present and these E2 induced survival effects are partly
mediated by Ras/ ERK signaling pathway. On the other hand, accumulation of BAD
(through transient overexpression) in the cells over a period of time (> 72 hrs) was
important to render cells unresponsive to mitogenic signals of E2, that are also partly
mediated by ERK mediated signaling mechanisms.

3.3 Summary
This study demonstrates that E2 inhibits apoptosis in MCF-7 cells by enhanced
phosphorylation of BAD, and indicates that BAD inactivation results from activation of
Ras/ERK/p90RSK and Ras/PI-3K/Akt pathways by E2. Data also indicate that BAD plays
an essential role in apoptosis induced by H2O2, TNFα and serum withdrawal.
Interestingly, data also indicate that even the double phosphorylation site mutant of BAD
(S75/99A) is inactive as an inducer of apoptosis in the absence of an apoptotic stimulus
(Figure 3.1), an observation that agrees with the BAD knockout study (71) where the
knocked in BAD S75/99A mutant did not induce death in mouse or MEFs rather
sensitized them to apoptotic agents like TNFα and growth factor withdrawal.
BAD also plays a decisive role when breast cancer cells have to respond to
mitogenic signals. Its negative influence on AP-1 mediated cyclin D1 expression may
play an important role to maintain the correct level of cell cycle progression under normal
conditions. For a successful mitogenic response to occur, BAD’s negative regulation
needs to be decreased, possibly by dissociating BAD/c-Jun interactions that may be
found proximal to chromatin (Figure 3.2). When mitogen fails to counteract the
enhanced negative regulation of cell cycle by elevated levels of BAD, cells may submit
to reduce proliferation and subsequently programmed cell death. The interplay of above
discussed factors can be summarized by the scheme shown in Figure 3.3.
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Mechanisms that mediate E2 induced anti-apoptosis
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Figure 3.3
Proposed outcomes due to E2 and BAD interaction in MCF-7 cells
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3.4 Prospects
Identification of genomic targets for BAD
Effects of exogenous BAD on AP-1 binding elements in cyclin D1 natural promoter
warrant further investigation of genomic targets of BAD. This can be approached in
several different ways.
(1) DNA sequences that bind with BAD (directly or indirectly) can be isolated by
the Chromatin immuno precipitation (ChIP) coupled with BAD specific antibody. In this
method protein/protein and protein/DNA are reversibly cross-linked and
immunoprecipitated with BAD specific antibody. The resulting complex can be used to
detect interacting proteins as well as nucleic acid sequences.
(2) Gene targets that are up or down regulated due to BAD overexpression can be
analyzed by Gene array technique. The arrays tailored for specific pathways are
commercially available.

Significance of BAD phosphorylation in cell cycle regulation
Failure of the unphosphorylatable BAD mutant to suppress cell cycle progression calls
for further verification of the role of these phosphorylation sites. Phospho-mimicking
(serine sites mutated to glutamate or aspartate) mutation to BAD can be used to address
this issue. If the cell cycle suppression and the up stream effects on c-Jun and cyclin D1
can be restored by these mutations, a precise role of BAD phosphorylation can be
defined.

Significance of BAD and c-Jun interaction in cyclin D1 expression
BAD and c-Jun interaction at the nuclear level was demonstrated by immunoprecipitation
assays. Similarly, BAD depletion from nuclear extract reduced the AP-1/TRE and
nuclear factor interaction to an extent that is comparable to that of dominant negative cJun. Sequestration of c-Jun by BAD can be deduced from these observations and can be
further verified by mammalian two-hybrid technique, where BAD and c-Jun can be
cloned into bait and target vectors respectively. In addition to c-Jun, other presumed AP1 molecules can be used as targets in this technique.
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Further, mutant forms of either molecule can be used to define the critical domains or
residues that are necessary the interactions.

BAD influence on signal mechanisms
Overexpression of wild type BAD abolished ERK and JNK signaling in response to 2-3
hr treatment of E2 and serum respectively. We also found that the ERK response for E2 is
bi-phasic (transient/rapid and sustained) and the rapid phase signal is presumed to
inactivate BAD’s apoptotic effects whereas the sustained signal may be required for the
mitogenic effect. Our data suggest a role for BAD as a regulator for the second phase of
E2 induced ERK signaling, that is reflected by its effects on cell cycle progression.
Detailed kinetics of E2 induced ERK signaling under the conditions of BAD overexpression and knockdown is desired.
Accelerated dephosphorylation of these molecules by BAD is likely and, the activities of
phosphatases need to be assayed. Within the cells, the interacting signal molecules are
mostly found in clusters (enzyme and substrate docking via special domains) and BAD’s
role in modulating these interactions can be analyzed.

Generation of cell lines that express BAD (wild type and mutants) in a regulated
manner
Cells that stably express the desired molecule are more advantageous than transient
expression. When a stable expression is under a regulated promoter (e.g. tetracycline
responsive) the molecule can be expressed at desired levels and the effects can be
analyzed. Cell lines that express BAD (wild type and mutants) in a regulated manner can
be very useful to carry out various experiments that have been suggested above.
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Chapter 4
Materials and Methods

4.1 Cell Culture
MCF-7 cells (a gift from R. P. Shiu (84)) were cultured in Dulbecco’s modified Eagles’s
medium (Sigma St. Louis, MO) supplemented with 5% fetal bovine serum (FBS),
penicillin G and streptomycin at 37° C in 5% CO2.
T47D (ATTC) were grown in DMEM/F12 (1:1) supplemented with 5% fetal serum,
penicillin G and streptomycin at 37° C in 5% CO2.

Growth arrest
Complete serum/growth factor withdrawal
Cells (MCF-7) were kept in 1% FBS for 24 hrs in DMEM (phenol red [PR] free) medium
and completely serum withdrawn for additional 36-48 hrs before the experiments.
Using anti estrogen and low serum
Cells (MCF-7 and T47D) were kept in 10nM ICI182,780 and 0.2% FBS for 48 hrs. Both
these methods arrested cells at G1 (at least 80% of the population was found to be in G1
as measured by DNA profiling using flow cytometry).

Treating growth arrested cells
Prior to treatments, cells were washed once with warm PBS and treated in medium free
of serum and PR.
LY294002 (5µΜ in MTT assay, 20µΜ in other assays), PD98059 (50µM) [Sigma] and
ICI182, 780 (1µM) [gift from Zeneca Pharmaceuticals], were used alone or added 1 hr
prior to other growth factors and E2.
E2 was used at 1nM in MTT assay and 10nM in other assays.
IGF-1 was used at 10ng/ml. Cells were treated with DMSO or EtOH as vehicle controls.
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4.2 Transient Expression of Desired Molecules with Adenoviral and
Plasmid Vectors
Adeno viruses
PTEN and DnAkt [kind gifts from Drs. R Bookstein, (53) and K Walsh (157)
respectively] and control vector LacZ [Q.Biogene - Carlsbad, CA] were transduced at 60,
30 and 30 MOI respectively. Optimum MOIs were determined by analyzing DNA
profiles (by flow cytometry) in response to virus dosage. Cells at 20-30% confluence
were infected in complete growth medium for 2 hrs. After the infection, cells were
recovered for 3-6 hrs in growth medium; growth arrested and treated as desired. To study
DNA fragmentation with TNFα or H2O2, cells were maintained in DMEM (PR free) with
2.5% FBS for 48 hrs after infection followed by induction of apoptosis.
Plasmids
Cells were transfected with various plasmid vectors using Lipofectamine PlusTM reagent
according to the manufacture’s [Invitrogen, Carlsbad, CA] protocol. Fifty to 80%
transfection efficiency was obtained as determined by the expression levels of EGFP
(microscopic and flow cytometry analysis).
Following is a list of plasmids used in this study.
Flag tagged human BAD wild type (wt) and human BAD serine75 and serine99
(equivalent to mouse serine112 and serine136 respectively) mutated to alanine were
kindly donated by Dr. HG Wang (119)
GFP tagged human wtBAD
RasN17, RasV12T35S (kindly donated by Drs. G L Johnson and C M Counter (110)
respectively)
AP-1 luciferase (kindly donated by Dr. Ben Dibling
Tetracycline response element (TRE) luciferase (ClonTech)
Human c-jun (kindly donated by Dr. Anders Strom)
Myristylated AKT (kindly donated by Dr. Antonio Cuadrado)
Cyclin D1 promoter luciferase constructs (kind gift from Dr. Pestell)
v-jun (Kindly donated by Dr. Vogt)
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4.3 Endogenous BAD Knockdown
Using BAD anti-sense oligonucleotides
BAD antisense oligonucleotides with phosphorothioate linkages were synthesized and
purified by Sigma-Genosys, Woodlands, TX. Cells were transfected twice (48 hrs apart)
with Lipofectamine Plus TM or RNAifect reagent according to the manufacture’s
[Invitrogen, Carlsbad, CA] protocol. Transfections were carried out in 6 well plates
using 1−3 µg of oligonulceotide per well. Antisense oligonucleotides used in this study
encoded complementary sequences to the coding regions including translation initiation
(BAD antisense 1) and termination codon (BAD antisense 2) sites for the human BAD
gene. Oligonucleotide sequences used were BAD antisense 1; 5’TGGGATCTGTAACATGCT-3’, BAD antisense1 (scrambled/control); 5’GGTTAGGTCAATTACTCG-3’, BAD antisense 2; 5’- CGAAGGTCACTGGGA-3’.

Using BAD siRNA
For the RNA interference siRNA for human BAD was purchased from Cell Signal
Technology (Cat# 6471). Transfection was done at the final concentration of 33nM of
siRNA with RNAifect according to the manufacturer’s protocol.

4.4 Cell Survival Assay using MTT
3-4,5-dimethylthiozol-2, 5-diphenyl-tetrazolium bromide (MTT) was used to measure the
amount of functional mitochondria hence the amount of live cells.
At 20-30% confluence, cells were treated in triplicates in 24 well plates. At 24 hr
intervals, MTT assay was performed according to the manufacture’s [Sigma] protocol.
Briefly MTT (5mg/ml) was added to equal one-tenth of the culture volume, and followed
by incubation for 3 hrs. Medium was removed and the converted dye was solubilized in
ice-cold isopropanol. Absorbency of dye was measured at 560nm with background
subtraction at 630nm on a micro plate reader [EL 340 Bio Kinetics Reader- BIO-TEK®
instruments].
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4.5 Induction and Assessment of Apoptosis
(1) Apoptosis was induced with H2O2 (2mM) for 1.5 hrs, TNFα (10ng/ml) for 8 hrs or by
complete serum withdrawal for 72 hrs, or with indicated constructs (where appropriate).
Cells were pretreated with E2 or IGF-1 for 1 hr prior to apoptotic stimuli.
ELISA assay kit [Cell death ELISA, Roche Diagnostics, Indianapolis IN] was used with
slight modification to the manufacture’s protocol to quantify DNA fragmentation.
Briefly, 50,000 cells (of each treatment) were lysed in 100µl of lysis buffer and a fraction
of the supernatant was subjected to reaction for 2 hrs with the immunocomplex of antiDNA-conjugated with peroxidase which binds to nucleosomal DNA, and anti-histonebiotin which interacts with streptavidin-coated wells in a micro titer plate. At the end of
the incubation, substrate was added and color development was quantified at 405nm
wavelength.
(2) DNA content was analyzed by flow cytometry and the sub G1 population was
considered as apoptotic (203).

4.6 Microscopic Analysis of Fluorescent-labeled Cells (fluorescence and
confocal microscopy)
Cells grown on cover slips were, transiently transfected with (i) indicated vectors and
green fluorescent protein (EGFP, 15% of total DNA) for co-expression studies (we have
previously validated the co-expression of plasmid constructs in MCF-7 cells (93)), (ii)
Flag tagged constructs, or left untrasfected. All trasfections were carried out using
Lipofectamine PlusTM reagent.
For anti-body staining: cover slips were fixed in 3% paraformaldehyde in PBS,
permeabilized with 0.1% Triton X-100 (in PBS) and blocked with (100% goat serum and
1% BSA) for 30 min at room temperature. Cover clips were incubated with primary
antibody solutions (made in blocking buffer according to the manufacturer’s instructions)
overnight at 40C. Cover slips were washed 5 times with PBS incubated with fluorescent
conjugated secondary antibodies for 2 hrs at room temperature. After washes with PBS
nuclei were stained with 3 µg/ml Hoechst 33342 [Sigma St. Louis, MO]. Cover slips
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were mounted on to glass slides and analyzed using a fluorescence microscope (Leitz
DMRB) or the confocal microscope.
For EGFP expressing cells: cover slips were fixed and nuclei were stained as above.

4.7 Western blot Analysis
Cells were washed once with ice-cold PBS and lysed in buffer containing 50mM TrisHCl, 1% NP-40, 0.25% sodium deoxycholate, 150mM NaCl, 1nM EGTA, 1mM PMSF,
1µg/ml leupetin, 1mM NaVO3, 1mM NaF.
For PARP cleavage detection, cells were lysed in ice-cold buffer containing 50mM TrisHCL, 6.5M Urea, 5% mercaptoethanol, 2% SDS and protease inhibitors; sonicated for 20
seconds and briefly centrifugated to remove cell debris (292).
For cytochrome-C detection, cytosolic fraction was prepared as described under ‘cell
fractionation’.
Aliquots of cell extracts containing 50-100 µg of total proteins or immunoprecipitates of
the indicated proteins were resolved on SDS-PAGE, transferred to nitrocellulose
membranes and probed with specific antibodies to phospho ERKs (pTEpY) [PromegaMadison, WI], phosphor BAD (S112 and S136) [Upstate Biotechnology-Lake Placid,
NY], ERK2, PTEN, BAD, PARP, cytochrome-C, Ras, phospho c-jun, cyclin D1, Akt
[Santa Cruz Biotechnology-Santa Cruz, CA] and c-jun [Neomarkers], followed by the
appropriate secondary antibody conjugated with HRP [Santa Cruz Biotechnology].
Proteins were detected by ECL™ [Amersham Life Science Ltd-Piscataway, NJ] and
examined by X-ray films. The band intensities/ fold activities were measured by Sigma
Gel™ software [Jandel Scientific-Winooski, VT].

4.8 Cell Fractionation
Nuclear and cytosolic fractions
Cytosolic and nuclear fraction were prepared as described in (119) with some
modifications. Cells (~10 million cells) were suspended in 150µl of hypotonic buffer
containing 3.3mM Hepes, pH7.5, 1.7mM KCl, 0.25mM MgCl2, 0.2mM EGTA, 0.2mM
EDTA, 5µg/ml leupeptin, 0.3mM PMSF, 16.7mM NaF, 66.7µM Na3VO4 and 8.3mM
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sodium β-glycerophosphate. After incubation on ice for 30 min, cells were homogenized
with a Dounce homogenizer and centrifuged at 1000g for 5 min at 4°C to collect the
nuclei. The resulting supernatant was centrifuged at 10000g for 10min at 4°C to obtain
the heavy-membrane fraction (pellet) and the cytosol (supernatant).
The nuclear pellet was resuspended in 50µl of buffer containing 20mM Hepes pH7.5,
1.5mM MgCl2, 420nM NaCl, 0.2mM EDTA, 25% v/v Glycerol, 0.3mM PMSF and
5µg/ml leupeptin, and incubated on ice with vigorous agitation (using small magnetic
bar) for 30 min. Nuclear extract (supernatant) was recovered after centrifugation at
5000g for 10 min at 4°C.

4.9 Immunocomplex Kinase Activity Assays
Radioactive method
Antibodies against ERK2, Akt, GSK3β, p85 (PI-3K) and protein A/G plus beads were
purchased from Santa Cruz Biotechnology. Anti p90RSK1antibody, soluble BAD and
IRS-1 were purchased from Upstate Biotechnology-Lake Placid, NY. Myelin Basic
Protein (MBP) was from GIBCOBRL-Carlsbad, CA. 100-200 µg total protein was
immunoprecipitated with antibody in excess and protein A/G plus beads at 4°C
overnight. Precipitates were washed three times with TG buffer (250mM NaCl, 20mM
Tris, 0.5% NP 40) and once with kinase buffer (50mM Hepes pH 7.4, 15mM MgCl2).
Kinase reactions were performed by incubating immunoprecipitates and the specific
substrates (0.2-1µg per sample) in kinase mixture (20µM ATP, 5µCi (γ 32P) ATP, 1mM
dithiothreitol and 0.1 mM Na3VO4 in kinase buffer) for 30 min at room temperature.
Reactions were stopped with 4X Laemmli’s sample buffer and proteins were resolved on
SDS-PAGE. Band intensities of phosphorylated substrates in autoradiograms were
measured by densitometry.

Phosphorylation assay (non-radioactive) with BAD GST fusion proteins
p-GEX-BADwt/mutant (kindly donated by Drs. P Cohen, (175) and AM Tolkovsky(279))
were grown in E.coli and proteins were isolated using glutathione-agarose beads (Sigma)
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followed by elution in the presence of reduced glutathione. Ten µg of BAD protein was
incubated with 75 µg of whole cell lysate in 50 µl of kinase buffer in the presence of
25µM ATP for 30 min in room teperature. At the end of the reaction 15 µl of agarose
conjugated glutathione was added and shaken for 1 hr at 4°C. Beads were collected,
washed three times with TG buffer and resuspended in 25 µl of 2X Laemmli’s sample
buffer.

4.10 Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts for EMSA was prepared as described above (3.8). Gel Shift assay
system (Cat# E3300) was purchased from Promega (Madison, WI). The AP-1 and
control elements were labeled with (γ-32) ATP and non denaturing 4% acrylamide gels
were prepared according to the manufacture’s protocol. DNA binding reactions were
carried out using 50µg of nuclear extract, radio labeled probe and gel shift binding buffer
with relevant volume of nuclease free water as described by the manufacturer. At the end
of the incubation period, reactions were resolved on non-denaturing acrylamide gel. Gels
were dried and auto-radio grams were obtained.

4.11 Reporter Assay
AP-1/TRE and cyclin D1 luciferase constructs were expressed in MCF-7 and T47D cells
as described in results and figure legends. After the desired periods of expression, cells
were rinsed with PBS and lysed with minimal volume of 1X reporter lysis buffer
(Promega Cat#E3971) [100 µl of lysis buffer for 1 well of a 6 well plate] on ice for 10
min. Supernatant was collected after brief centrifugation (12,000g for 2 min at 40C). 50
µl of cell lysate and 100 µl of Luciferase Assay Substrate (Promega Cat#E4030) were
mixed and emission of light was measured using the scintillation counter. For
consistency in measuring luciferase activity, each sample reaction was initiated
immediately before the measurement and reading. To measure the level of luciferase
vector expression, EGFP was co-expressed and EGFP levels were analyzed by the
Western blotting.
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4.12 DNA Profile by Flow Cytometry Analysis
Single cell suspension of harvested cells was fixed in 70% cold ethanol, pelleted and
washed with PBS. Cells were then incubated in propidium iodide staining solution
(1µg/ml) in the presence of RNAse in PBS for 30 mins to 1 hr at room temperature, in
dark.

4.13 Metabolic labeling with 35(S) methionine
MCF-7 cells were transiently transfected with desired constructs. Twenty four -48 hours
after the transfection, cells were cyctine/methionine deprived for 1 hr (methionine free
Dulbecco’s MEM/F12) and labeled with Trans 35S (75µci/ml) in the same medium for
desired period of times. Labeling medium was removed and the cells were washed twice
with cold PBS. Cells were lysed and indicated proteins were immnuoprecipitated from
whole cell extracts. Immunoprecipitates were resolved using 12% SDS-PAGE. Gels
were dried and exposed to X-ray film. Intensity of the band denotes the amount of 35S
methionine incorporated within the labeling period.
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